Investigation of the molecular background of alternative pathway dysregulation in thrombotic microangiopathies by Trojnár, Eszter
Investigation of the molecular background of alternative 





Eszter Trojnar, MD 
 





Supervisor:    Zoltán Prohászka, MD, D.Sc 
Official reviewers:  Csaba Kálmán Ambrus, MD, PhD 
    Judit Müller, MD, PhD 
 
Head of the Complex Exam Committee:   Zoltán Benyó, MD, D.Sc 
Members of the Complex Exam Committee:  Hargita Hegyesi, Ph.D 






TABLE OF CONTENTS 
1. LIST OF ABBREVIATIONS        6 
2. INTRODUCTION         10 
2.1. Pathophysiology of the complement system    10 
2.1.1. Physiological activation of the complement system 
and significance of the alternative pathway   10 
2.1.2. Regulation of the complement system    13 
2.1.3. Regulation of the alternative pathway    15 
2.1.4. Significance of Factor H in the regulation 
of the alternative pathway      16 
2.1.5. Role of pentraxins in complement regulation   18 
2.1.6. Dysregulation of the complement alternative pathway  22 
2.2. Thrombotic microangiopathies      25 
2.2.1. Classification and pathogenesis of thrombotic microangiopathies 25 
2.2.2. Thrombotic thrombocytopenic purpura    25 
2.2.3. Typical hemolytic uremic syndrome    26 
2.2.4. Atypical hemolytic uremic syndrome    26 
2.2.5. Secondary thrombotic microangiopathies    28 
2.2.6. Pathological complement activation 
in thrombotic microangiopathies     28 
2.2.7. Alternative pathway dysregulation associated with 
anti-Factor H antibodies in atypical hemolytic uremic syndrome 32 
2.2.8. Factor H-related proteins and their genetic-linkage 
to anti-Factor H antibodies      33 
3. SPECIFIC AIMS         36 
3.1. Analysis of the association between systemic pentraxin levels 
and laboratory signs of disease activity in thrombotic microangiopathies 36 
3.2. Investigation of the relation of complement overactivation and systemic 
pentraxin levels in distinct forms of thrombotic microangiopathies  36 
3.3. Epitope analysis of anti-Factor H antibodies 




4. METHODS          38 
4.1. Patient selection, sample collection and study design   38 
4.1.1. Sample collection from patients at the acute phase of 
thrombotic microangiopathy      38 
4.1.2. Sample collection from autoimmune 
atypical hemolytic uremic syndrome patients   41 
4.2. Determination of laboratory parameters in patients 
at the acute phase of thrombotic microangiopathy    43 
4.3. In vitro assessment of pentraxin-3 effect on 
alternative pathway activation      43 
4.4. Determination of anti-Factor H antibody levels    44 
4.5. Peptide synthesis for epitope mapping     44 
4.6. Antibody binding to the immobilized synthetic peptides of Factor H 
and Factor H-related protein 1      46 
4.7. Synthesis and antibody binding of recombinant Factor H 19-20 mutants 47 
4.8. Visualization of the linear epitopes and point mutations 
on the folded Factor H structure      47 
4.9. Statistical analysis        48 
5. RESULTS          49 
5.1. Analysis of the association between systemic pentraxin levels and 
laboratory signs of disease activity in thrombotic microangiopathies 49 
5.1.1. Characteristics of patients with acute phase thrombotic 
microangiopathy selected for the determination of 
the systemic pentraxin levels     49 
5.1.2. Pentraxin levels in acute phase thrombotic microangiopathy 
and their relation to the laboratory markers of disease 
and clinical characteristics of patients    52 
5.1.3. Association of the systemic pentraxin levels 
with the acute phase mortality     58 
5.1.4. Pentraxin levels in disease remission    58 
5.2. Investigation of the relation of complement overactivation and systemic 
pentraxin levels in distinct forms of thrombotic microangiopathies 63 
DOI:10.14753/SE.2020.2318
4 
5.2.1. Laboratory signs of complement consumption in acute phase 
thrombotic microangiopathy and their association to the systemic 
pentraxin levels       63 
5.2.2. Impact of excess pentraxin-3 on 
alternative pathway activity in vitro     70 
5.3. Epitope analysis of anti-Factor H antibodies 
in atypical hemolytic uremic syndrome     72 
5.3.1. Clinical and laboratory characteristics of patients with autoimmune 
atypical hemolytic uremic syndrome     72 
5.3.2. Localization of the linear autoantibody epitopes on Factor H in the 
acute phase and remission of atypical hemolytic uremic syndrome 74 
5.3.3. Comparison of Factor H autoantibody binding to linear epitopes on 
Factor H and Factor H-related protein 1    74 
5.3.4. Fine epitope mapping of recombinant Factor H domains 19-20 
expressing atypical hemolytic uremic syndrome-associated point 
mutations by anti-Factor H autoantibodies of 
atypical hemolytic uremic syndrome patients    81 
5.3.5. Position of the linear Factor H epitopes and atypical hemolytic 
uremic syndrome-associated point mutations on 
the crystal structure of Factor H     83 
6. DISCUSSION         86 
6.1. Elevation of the systemic pentraxin levels in the acute phase of 
thrombotic microangiopathies and their association to complement 
overactivation and consumption      86 
6.2.  Epitope analysis of anti-Factor H antibodies    90 
7. CONCLUSIONS         95 
8. SUMMARY          96 
9. ÖSSZEFOGLALÁS         97 
10. BIBLIOGRAPHY         98 
11. LIST OF PUBLICATIONS        120 
11.1 Publications related to the Ph.D. dissertation of the candidate  120 
11.2 Publications independent of the Ph.D. dissertation of the candidate 120 
DOI:10.14753/SE.2020.2318
5 
12. ACKNOWLEDGEMENT        121 
DOI:10.14753/SE.2020.2318
6 
1. LIST OF ABBREVIATIONS 
Acm – acetamidomethyl 
ANC – absolute neutrophil count 
ADAMTS13 – a disintegrin and metalloproteinase with a thrombospondin type 1 motif 
member 13 
ADAMTS13 – the gene encoding a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif member 13 
aHUS – atypical hemolytic uremic syndrome 
AMD – Age related macular degeneration 
Anti-FH antibody – anti-Factor H antibody 
AP – alternative pathway 
Arg – arginine 
Asp – aspartic acid 
Boc – tert-butyloxycarbonyl 
C1-INH – C1-inhibitor 
C1q – complement component 1q 
C3 – complement component 3 
C3 – the gene encoding the complement component 3 
C3a – complement component 3a 
C3b – complement component 3b 
C3bBbP – Alternative pathway C3 convertase stabilized by properdin 
C3c – complement component 3c, cleavage product of the complement component 3b 
C3d – complement component 3d, cleavage product of the complement component 3b 
C3dg - complement component 3dg, cleavage product of the complement component 3b 
C3G – C3 glomerulopathies 
C3Nef - C3 Nephritic Factor 
C4 – complement component 4 
C4BP – C4b binding protein 
C4c – complement component 4c, cleavage product of the complement component 4b 
C4d – complement component 4d, cleavage product of the complement component 4b 




CD59 – cluster of differentiation 59 
CFB – the gene encoding the complement protein Factor B 
CFH – the gene encoding the complement protein Factor H 
CFHR1-5 – the genes encoding Factor H-related proteins 1-5 
CFI – the gene encoding the complement protein Factor I 
CP – classical pathway 
CR – complement receptor 
CRIg – complement receptor of the immunoglobulin family 
CRP – C-reactive protein 
Cys – cysteine 
DAF – decay accelerating factor 
DAMP – danger associated molecular pattern 
DGKE – the gene encoding diacylglycerol kinase epsilon 
DMF – Dimethylformamide 
ELISA – enzyme-linked immunosorbent assay 
FB – complement Factor B 
FFP – fresh frozen plasma 
FH – Factor H 
FHR 1-5– Factor H-related proteins 1-5 
FI – complement Factor I 
Fmoc/tBu - fluorenylmethyloxycarbonyl group/ tertiary butyl group 
FRETS-VWF73 – Fluorescence-Quenching Substrate for a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif member 13 
GAG – glycosaminoglycan 
Glu – glutamic acid 
GPI – glycosylphosphatidylinositol 
His – histidine 
HSP60 – heat shock protein 60 
HUS – hemolytic uremic syndrome 
iC3b – inactive cleavage product of the complement component 3b 
iC4b – inactive cleavage product of the complement component 4b 
IgA – Immunoglobulin A 
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IgG – Immunoglobulin G 
IgG-HRP - Immunoglobulin G conjugated to horseradish peroxidase 
IgM – Immunoglobulin M 
LDH – lactate dehydrogenase 
LPS – lipopolysaccharide 
Lys – lysine 
MAC – membrane attack complex 
MAp19 – Map19 protein, smaller alternative splice product of the gene encoding 
mannose-binding lectin-associated serine protease-2 
MAp44 – mannose-binding lectin-associated protein of 44 kDa 
MASP-1, -2, -3 – mannose-binding lectin-associated serine proteases 1, 2 and 3 
MBL – mannose-binding lectin 
MCP – membrane cofactor protein 
MLPA – multiplex ligation-dependent probe amplification 
MMACHC – the gene encoding methylmalonic aciduria and homocystinuria type C 
protein 
MMACHC-TMA – thrombotic microangiopathy associated to methylmalonic aciduria 
and homocystinuria, cobalamin C complementation type 
NET – neutrophil extracellular trap 
NHS – normal human serum 
NLRP3 – NACHT, LRR and PYD domains-containing protein 3 
N -Fmoc – N-(9-Fluorenylmethoxycarbonyl) 
OD – optical density 
OtBu – tertiary butyl ester 
PAMP – pathogen associated molecular pattern 
Pbf – 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PBS - phosphate-buffered saline 
PEX – plasma exchange therapy 
PIGA –phosphatidylinositol glycan anchor biosynthesis class A gene 
Pmc – 2,2,5,7,8-pentamethyl-chroman-6-sulphonyl 
PRM – pattern recognition molecule 
PTX3 – pentraxin-3 
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RCA – regulators of complement activation 
sC5b-9 – soluble form of the membrane attack complex, consisting of complement 
components 5b to 9 
SCR – short consensus repeat 
Ser – serine 
SFTL – a unique amino acid sequence on the C-terminal end of the Factor H-like 
protein 1 consisting of serine, phenylalanine, threonine and leucine 
STEC – Shiga toxin-producing Escherichia coli 
STEC-HUS – Shiga toxin-producing Escherichia coli-associated hemolytic uremic 
syndrome 
Stx – Shiga-toxin 
tBu – tertiary butyl group 
Tert-butyl ether – tertiary butyl ether 
THBD – the gene encoding thrombomodulin 
THBD – thrombomodulin 
Thr – threonine 
TMA – thrombotic microangiopathy 
TMB - 3,3 ,5,5 -tetramethylbenzidine 
TTP – thrombotic thrombocytopenic purpura 
Tyr – tyrosine 
ULVWF – ultra-large form of von Willebrand Factor 




2.1. Pathophysiology of the complement system 
2.1.1. Physiological activation of the complement system and significance of the 
alternative pathway 
The complement system is an integral part of the innate immune system that contributes 
to the elimination of invading pathogens, immune complexes and maintains continuous 
clearance of redundant cellular debris together with the regulation of the innate immune 
response (Kavanagh et al. 2013). Complement activation is triggered by the recognition 
of molecular patterns characteristic to microorganisms or modified host tissues 
(pathogen and danger associated molecular patterns, PAMPs and DAMPs, 
respectively). Binding of such activators induces the initiation of the proteolytic cascade 
of complement that ultimately leads to the elimination of the activator either through 
opsonization or direct lysis, in addition to the simultaneous alarm of both innate and 
adaptive immunity (Ricklin et al. 2010, Bajic et al. 2015). Complement activation may 
occur via the simultaneous or distinct initiation of three major pathways, the classical, 
the lectin and the alternative pathways (CP, LP and AP, respectively). While each of the 
activation pathways has its specific triggers of activation and plays a well-defined role 
in the effector functions of complement, full-blown activation of the individual 
pathways converges on the level of the C3 molecule, cleavage of which initiates the 
mutual, terminal pathway of complement and leads to the attack and lysis of the target 
molecule. 
The CP of complement is initiated via the surface binding of the C1 complex, a flexible 
assembly formed by the pattern recognition molecule (PRM) C1q (Wallis et al. 2010) 
and a heterotetramer of the serine proteases C1r2s2 (Gaboriaud et al. 2014). Target 
recognition of C1q, either through direct binding of PAMPs and DAMPs, or via the 
recognition of surface-bound PRMs including immunoglobulins and pentraxins (Ricklin 
et al. 2010), triggers autoactivation of C1r and thus cleavage of C1s (Gaboriaud et al. 
2004, Mortensen et al. 2017). Activated C1s in turn will be capable of the cleavage of 
the C4 and C2 molecules. The subsequent generation of C4a and C4b exposes a 
previously hidden thioester bond on C4 that allows for the covalent surface attachment 
of C4b (Ricklin et al. 2010), hence opsonization of the target tissue, whereas cleavage 
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of C4b-bound C2 molecules results in the formation of the CP C3 convertase C4bC2a 
(Mortensen et al. 2017). 
The activation of the lectin pathway is initiated in a similar manner as that of the CP. 
Even though, primary activation triggers of the LP are surface glycoprotein and 
glycolipid patterns characteristic to invading microorganisms (Bajic et al. 2015), 
recognition of host cell organelles, e.g. mitochondria (Brinkmann et al. 2013) may also 
provide an activation trigger of the LP. Target surfaces are recognized by mannose-
binding lectin (MBL), collectins and ficolins, specific PRMs of the LP (Ricklin et al. 
2010). Target binding of the LP PRMs activates the MBL-associated serine proteases 
(MASPs) via the intermolecular cleavage of MASP homodimers complexed to distinct 
PRMs (Mortensen et al. 2017). This leads to the downstream cleavage of complement 
factors C4 and C2, thus aiding the formation of the LP C3-convertase (C4bC2a). Since 
activation of MASP-2 is inevitable for the cleavage of both C2 and C4 (Matsushita et al. 
2000, Rossi et al. 2001) and MASP-1 is the exclusive activator of MASP-2 (Heja et al. 
2012), the two serine proteases have to be positioned in close proximity for the 
induction of the downstream proteolytic activity of MASP-2. This resembles a major 
difference between the initiation of the CP and LP. Whereas CP protease activation is 
induced by conformational changes within the C1 complex, initiation of the LP requires 
inter-complex protease activity, thus accentuating the role of the glycan pattern in the 
clustering and correct orientation of the MASP/PRM complexes (Degn et al. 2014, 
Mortensen et al. 2017). 
The AP plays a dual role in the activation of complement. On the one hand, it has a 
baseline, continuous activation, whereas on the other hand the AP may amplify the 
intensity of complement activation launched through the CP and LP (Sanchez-Corral et 
al. 2018). The baseline activation of the AP is initiated by the spontaneous hydrolysis of 
C3 in the fluid phase. In the end product of hydrolysis (C3(H2O)) the thioester bond of 
the C3 molecule becomes accessible and allows the binding of Factor B (FB). Then, 
Factor D-mediated cleavage of FB activates the preformed AP C3 pro-convertase 
(C3bB or C3(H2O)B, respectively) (Harrison 2018). Following this, the activated AP 
C3 convertase (C3bBb or C3(H2O)Bb) is able to cleave further C3 molecules, and the 
resulting cleavage product (C3b) may be deposited to nearby surfaces, thus providing 
basis for the amplification of complement activity. Moreover, C3 convertase activity of 
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the CP and LP also results in the generation of surface-bound C3b that may engage 
additional activated FB molecules and hence induce the assembly of further AP C3 
convertases (Bajic et al. 2015). The AP C3 convertase however quickly dissociates 
upon activation with a half-life of approximately 90 seconds at 37oC, unless it is 
stabilized by properdin (Bajic et al. 2015). Properdin is the only positive regulator of the 
AP. It can stabilize the AP C3 convertase up to 60 minutes (Fearon et al. 1975) and it 
may direct fluid phase C3b or C3(H2O) to complement activator surfaces such as 
activated platelets, apoptotic or necrotic cells and invading pathogens (Kemper et al. 
2008, Cortes et al. 2012, Saggu et al. 2013). 
C3b is the major opsonin of the complement system, which similarly to C4b, carries a 
thioester bond that allows for the covalent attachment to hydroxyl groups of 
carbohydrates, present on all biological surfaces (Law et al. 1997). Although C3b may 
be deposited to host and non-host tissues alike, surface binding only occurs in the 
immediate vicinity of complement activation, provided by the rapid hydrolysis of its 
thioester bond following C3 cleavage (Law et al. 1997). Opsonization by C3b 
stimulates phagocytosis of the complement activator including invading pathogens as 
well as DAMPs generated by endogenous tissues, hence providing a fundamental tool 
for the homeostatic elimination of cellular debris. 
Upon the assembly of a sufficient number of surface-bound C3b, the C3 convertase, 
regardless of its origin, may gather an additional C3b molecule, thus creating the C5 
convertase (C3bBb3b or C4b2a3b, respectively). Through cleavage of C5, the C5 
convertase initiates the downstream activation of the terminal pathway. This implies the 
formation of the membrane attack complex (MAC) via the assembly of C6, C7, C8 and 
multiple C9 molecules on target membranes of complement attack (Bajic et al. 2015). 
Contingent on the intensity of terminal pathway activation, the assembly of MACs may 
either lead to the lysis of the target cell or modify downstream cell signaling pathways 
through the assembly of a sublytic number of MACs (Tegla et al. 2011, Laudisi et al. 
2013, Triantafilou et al. 2013, Bajic et al. 2015). 
In addition to the launch of the succeeding step in the chain reaction of complement 
activation, cleavage of the complement factors C3 and C5 yields the powerful 
anaphylatoxins C3a and C5a. C3aR and C5aR1 receptor binding of these cytokines 
intensifies the pro-inflammatory response via evoking oxidative burst, synthesis and 
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release of inflammatory mediators and induction of chemotaxis (Klos et al. 2009, 
Laursen et al. 2012). 
PAMPs and DAMPs alike may create an activation trigger of the complement cascade. 
However, following the initial activation of the complement pathways, the intensity and 
amplifying capacity of the AP determines, whether the elicited response will recoil by 
opsonization and tagging of the elimination target or will induce the full-blown 
activation of the terminal pathway with the concomitant induction of an inflammatory 
response (Harboe et al. 2004). The significance of AP activation is corroborated by its 
quantitative role in the augmentation of complement activity. Irrespective of individual 
pathway initiation, the majority of surface-bound C3b is generated by the amplification 
loop of the AP (Harboe et al. 2004, Harboe et al. 2009). Since the produced opsonin 
may be deposited on all surfaces, including intact host tissues (Harboe et al. 2004, 
Harboe et al. 2009), their protection from complement attack requires the regulation of 
complement activity. 
2.1.2. Regulation of the complement system 
Under physiological conditions sufficient restrain of excessive complement activation is 
provided by specific fluid phase and surface-bound regulators of the complement 
system that are capable of complement inhibition as well as discrimination of host 
tissues from foreign structures. Restrain of complement activity may take place via 
multiple mechanisms. These include direct inhibition of the activator proteases, 
substrate-limited restrain of pathway initiation, decay acceleration of the formed C3 
convertases together with cofactor-mediated cleavage of complement activator proteins 
and inhibition of the terminal pathway or inactivation of the released anaphylatoxins. 
The initial activation steps of the CP and LP are kept under control by the shared fluid 
phase regulators C4b binding protein (C4BP) and C1-inhibitor (C1-INH). C1-INH is 
responsible for the irreversible blockade of both the C1-complex and MASPs via 
binding C1r and C1s, as well as MASP-1 and MASP-2 (Bajic et al. 2015). On the other 
hand, C4BP fills a dual function, aiding the dissociation of C2a from the CP C3 
convertase (C4bC2a) and acting as a cofactor in the Factor I (FI)-mediated breakdown 
of surface-bound C4b to iC4b and further to C4c and C4d. Furthermore, two additional 
members of the MASP protein family (MAp44 and MAp19) (Takahashi et al. 1999, 
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Degn et al. 2009) may participate in the regulation of the LP by inhibiting the formation 
of the MBL-MASP co-complexes and thus limiting the transactivation of MASPs 
(MAp44) (Garred et al. 2016) or via competition with MASP-2 in MBL binding 
(MAp19) (Iwaki et al. 2006), however the physiological relevance of the latter 
mechanism is challenged by the reportedly low affinity of MAp19 to MBL (Degn et al. 
2011). 
Regulation of the assembled C3 convertases (C4bC2a and C3bBb) determines the 
amplification capacity of complement. Deactivation of C4b and C3b (either tissue-
bound or as part of the activated C3 convertases) is regulated via two processes. Decay 
acceleration aids the dissociation of C2a or Bb from the preformed complexes, whereas 
surface-attached C3b and C4b are inactivated through FI-mediated cleavage that is 
substantiated by cofactors (Liszewski et al. 1991). Complement regulator proteins 
encoded in the regulators of complement activation (RCA) gene cluster may inhibit 
complement activation through both decay accelerating and cofactor activities. These 
proteins are encoded on chromosome 1 at q3.2 and consist of amino acid repeating 
motifs termed short consensus repeats (SCR) (Reid et al. 1986, Mayilyan 2012). The 
RCA family consists of both fluid phase (C4BP, Factor H (FH)) and host-cell expressed 
regulators (membrane cofactor protein (MCP), decay accelerating factor (DAF), 
complement receptor 1 (CR1), complement receptor 2 (CR2)) that are capable of the 
binding of C3b and C4b (Liszewski et al. 1991). 
Effector functions of the terminal pathway are kept under control by soluble as well as 
membrane-associated complement regulators. The former ones include clusterin that 
hinders the assembly of the MAC through the prevention of C9 binding to C5b-8 (Jenne 
et al. 1989, Tschopp et al. 1994) and vitronectin, which inhibits the membrane 
attachment of the C5b-7 complex, thus creating a soluble form of MAC (Podack et al. 
1978, Bajic et al. 2015), while the membrane expressed analogue of clusterin, CD59 
blocks the binding of C9 to C5b-8 and thus inhibits the polymerization of the C5b-9 
complex (Meri et al. 1990). 
Cytokines of the complement system are inactivated by carboxypeptidases that remove 
the C-terminal arginine residue of C3a and C5a, thus creating C3a-desArg and 
C5adesArg (Bokisch et al. 1970). Whereas C3a-desArg loses its signaling potential 
through the C3aR, C5adesArg maintains approximately 10% of the C5a activity. 
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Therefore, control of C5a activity is also sustained by the decoy receptor C5aR2 that 
aids the removal of C5a from the circulation, and as recently suggested, may induce the 
retrieval of helper T-cells by the inhibition of the NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) inflammasome (Arbore et al. 2016). 
2.1.3 Regulation of the alternative pathway 
Restriction of unwanted complement activation on intact host tissues requires tight 
regulation of the AP, given its significance in the amplification of complement activity. 
The rate limiting step of AP activation is the Factor D-mediated cleavage of FB, which 
is inevitable for the activation of the preformed AP C3 pro-convertase (C3bB or 
C3(H2O)B, respectively) (Harrison 2018). Since Factor D is present mainly in its active 
form in the human blood, provided by the physiological activation of its zymogen (pro-
Factor D) by MASP-3 (Yamauchi et al. 1994, Iwaki et al. 2011, Oroszlan et al. 2016) or 
additional serine proteases upon activation of the coagulation and complement cascades, 
(Yamauchi et al. 1994), pro-convertase activation via Factor D is limited by the 
accessibility of its substrate, FB. However, the CP regulator C1-IHN may limit the AP 
convertase assembly via interfering with the binding of FB to C3b, too (Jiang et al. 
2001). 
Nevertheless, once the AP C3 convertase is activated, its strict regulation is a key 
component in the restrain of complement amplification. Deactivation of the C3bBb 
complex occurs via both direct cleavage of C3b and decay acceleration of the active 
complex. During the initiation of the AP, cleavage of C3 exposes a reactive thioester 
domain necessary for the covalent attachment of C3b to nearby surfaces and also 
exposes the molecular regions involved in FB binding. However, repositioning of the 
thioester domain simultaneously generates an extended surface on C3b that allows for 
the binding of complement regulators. Thus, attachment of complement regulator 
proteins to C3b may interfere with FB binding and accelerate the decay of the AP C3 
convertase (Alcorlo et al. 2015). Furthermore, it allows the attached regulator to exert 
its cofactor activity in the FI-mediated degradation of C3b (Alcorlo et al. 2015) 
(Delvaeye et al. 2009, Kavanagh et al. 2013, Baines et al. 2017). Soluble or membrane-
bound cofactors of FI that participate in the regulation of the AP C3 convertase include 
FH, Factor H-like protein 1 (FHL-1), MCP, CR1, CR2 and THBD. FH and FHL-1 
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(discussed in detail below) are plasma proteins that may simultaneously bind C3b and 
host surface elements, and exert both cofactor as well as decay accelerating activities. 
MCP is a regulator ubiquitously expressed on all nucleus-bearing cells of the human 
body (Andrews et al. 1985). It is a glycosylphosphatidylinositol (GPI)-anchored protein 
that may bind both C3b and C4b. Complement receptors CR1 and CR2 are immune 
adherence receptors expressed mainly on erythrocytes and leukocytes. Whereas both 
proteins exert cofactor activities via binding of C3b and C4b or C3dg, respectively 
(Liszewski et al. 1991), CR1 also accelerates the decay of the active C3 and C5 
convertases (Baines et al. 2017). THBD, the major inhibitor of thrombin generation on 
endothelial cells, has been shown to enhance C3b cleavage via both FH-dependent and 
independent mechanisms (Heurich et al. 2016, Tateishi et al. 2016). Additionally, DAF 
inhibits the downstream assembly of both C3 and C5 convertases on the cellular-surface 
through its binding to surface-attached C3b and C4b (Medof et al. 1984) and 
substantiates the disassembly of the C3 convertases (Liszewski et al. 1991). Altogether, 
cleavage of C3b and acceleration of the decay of the preformed AP C3 convertases 
abrogates complement amplification and reduces the downstream activation of the C5 
convertase and the terminal pathway of complement. 
Beside the restrain of complex assembly, AP regulation is substantiated by the removal 
of the activator structures through the enhancement of phagocytosis. Following multiple 
cleavages of C3b, the emergence of more and more potent C3 degradation products 
(iC3b, C3c, C3dg) exposes binding sites for complement receptors (CR1-4 and CRIg) 
of immune effector cells, and stimulates macrophage phagocytic activity together with 
the initiation of adaptive immune responses (van Lookeren Campagne et al. 2007, Bajic 
et al. 2015). 
2.1.4. Significance of Factor H in the regulation of the alternative pathway 
Albeit regulation of the complement AP takes place through the joint interplay of 
complement regulator proteins, the most potent and abundant regulator of the AP is FH, 
a 155 kDa glycoprotein (Bajic et al. 2015, Sanchez-Corral et al. 2018), the systemic 
level of which ranges between 250-880 mg/L (Sanchez-Corral et al. 2018). FH is built 
up from 20 SCR domains that share a various degree of homology to one another and to 
SCR domains of other members of the FH protein family (Ripoche et al. 1988, Jozsi et 
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al. 2014). The N-terminal four SCR domains are responsible for the regulatory activities 
of FH (Gordon et al. 1995), whereas the C-terminal SCRs 19-20 and the middle SCRs 
6-8 are in charge of ligand binding by the regulator (Schmidt et al. 2008, Kopp et al. 
2012). These structural characteristics allow for the simultaneous binding of multiple 
ligands, while maintaining the AP regulatory activity both in the fluid and solid phases. 
FH regulates the AP via multiple mechanisms and targets complement activity through 
ligand-based discrimination of complement activator surfaces from intact host tissues 
(Meri 2016). 
FH may compete with FB in C3b binding, thus inhibiting the assembly of C3 as well as 
C5 convertases, both in the plasma and on cellular membranes. Furthermore, FH 
accelerates the decay of the preformed convertases by acting as a cofactor in the FI-
mediated degradation of C3b, while it may also anchor to the cell-bound degradation 
products C3c and C3d (Sanchez-Corral et al. 2018). 
FH has specific ligands on intact host tissues and dead or damaged cells targeted for 
elimination (Sanchez-Corral et al. 2018). Binding of glycosaminoglycans (GAGs), 
sialic acid and heparin anchors functionally active FH to the extracellular matrix or 
directly to the cell membrane of intact host tissues, thus preventing further complement 
activation on non-activator surfaces. In contrast, ligand binding on apoptotic and 
necrotic tissues including direct attachment to e.g. Annexin-II, deoxyribonucleic acid, 
histones and malondialdehyde epitopes or recruitment to damaged cells by ligand bound 
pentraxins (Bottazzi et al. 2010, Leffler et al. 2010, Weismann et al. 2011, Daigo et al. 
2016) compensates for the downregulation of membrane-expressed complement 
regulators and aids the silent elimination of these targets via opsonophagocytosis 
(Trouw et al. 2007). 
Divergence and overlaps in the epitopes of the distinct FH ligands play an important 
role in the context specific recruitment and correct positioning of FH, thereby localizing 
the complement inhibitory activity. For instance binding of C3b and its degradation 
products through both SCR domains 1-4 and 19-20 (Schmidt et al. 2008) provides 
structural basis for the recognition of C3b on host tissues via the simultaneous binding 
of host-specific GAGs and sialic acids (Morgan et al. 2011), and also permits the 
binding of additional C3b molecules attached to the same surface (Schmidt et al. 2008). 
Binding of fluid phase PRMs such as pentraxins likewise leaves room for C3b binding, 
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since the former involves both SCR domains 6-8 and 19-20 (Jarva et al. 1999, Deban et 
al. 2008, Kopp et al. 2012). In the meantime, the regulator maintains its functional 
activity exerted through the N-terminal four SCRs, both in the fluid phase and when 
attached to cellular surfaces (Sanchez-Corral et al. 2018). 
These structural and functional characteristics of FH significantly contribute to a 
targeted but at the same time restricted complement activation and an optimal degree of 
phagocytosis avoiding the unnecessary amplification of the complement cascade on 
intact host tissues during homeostatic clearance of cellular debris and also in the context 
of an infection. It is noteworthy however, that recruitment of functionally active FH is a 
well-evolved escape mechanism of tumor cells and pathogens from complement 
mediated killing. The FH binding site of such pathogens is also located on SRC 
domains 6-7 and 19-20, binding of which may provide molecular mimicry and also 
interfere with the physiological, host-cell associated functions of FH (Lambris et al. 
2008, Jozsi 2017). Since FH is the most important regulator of the continuously active 
AP, any dysfunction of the regulator or siege of its ligand binding sites may destroy the 
above described peculiar mechanisms of host-cell defense and lead to the dysregulation 
of the complement AP with destructive consequences (Kopp et al. 2012). 
In summary, the activation status of the AP and therefore that of the whole complement 
cascade is determined by the combined effect of activator and regulator mechanisms. 
Following the local initiation of the distinct complement pathways, the fate of the 
generated C3b depends on the strictly regulated balance of amplification and regulator 
factors (Harrison 2018), the dysfunction of which may lead to the dysregulation of the 
AP and the manifestation of complement-mediated diseases (Baines et al. 2017). 
2.1.5. Role of pentraxins in complement regulation 
Pentraxin-3 (PTX3) and C-reactive protein (CRP) are fluid PRMs that participate in the 
innate immune response via the recognition and binding of pathogenic moieties, 
opsonization of target cells and activation as well as regulation of the complement 
system (Figure 1) (Daigo et al. 2016). Members of the pentraxin family include short 
and long pentraxins that share a conserved pentraxin-like domain on their C-terminal 
ends (Daigo et al. 2016). The primary sequence of the long pentraxin PTX3 is also 
highly conserved among different animal species, and encodes a 381 amino acid long 
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protein with a unique N-terminal domain (Inforzato et al. 2013), not related to any 
known protein structure (Daigo et al. 2016). PTX3 is generated in response to 
inflammatory stimuli via gene expression induction in innate immune cells, endothelial 
cells and fibroblasts (Kunes et al. 2012). However, prompt release of PTX3 originates 
from neutrophil granulocytes (Kunes et al. 2012), where constitutively produced, 
glycosylated PTX3 monomers are stored in lactoferrin+ intracellular granules (Daigo et 
al. 2016). Upon neutrophil cell activation and neutrophil extracellular trap (NET) 
release, PTX3 is secreted from neutrophils and its monomers form octamers through 
inter-chain disulfide bonds (Daigo et al. 2016). 
CRP on the other hand is a member of the short pentraxin protein family (Daigo et al. 
2016). Its native, pentameric form is produced and stored in the endoplasmic reticulum 
of resting hepatocytes (Sproston et al. 2018). Upon inflammatory stimuli, CRP is 
secreted into the circulation and following the recognition of target cell membranes, its 
attachment to phosphocholine induces the disassembly of the pentameric structure to 
CRP monomers in a calcium-dependent fashion (Sproston et al. 2018). CRP is a 
routinely used biomarker of systemic inflammation in clinical setting, whereas PTX3 
was reported to be a prognostic marker of disease activity and severity in an increasing 
number of diseases (Maekawa et al. 2011, Lech et al. 2013, Speeckaert et al. 2013, 
Sjoberg et al. 2014, Krzanowski et al. 2017). 
Both molecules have been shown to interact with the complement system on multiple 
levels. PTX3 may initiate the activation of the CP and LP via binding to surface-
associated MBL (Ma et al. 2011), ficolins, collectins (Ma et al. 2009) and C1q (Nauta et 
al. 2003). MBL-bound PTX3 may even recruit C1q molecules to the activator surface 
thus providing a link between the activation of the LP and CP, whereas the interaction 
of PTX3 with C1q in the fluid phase inhibits CP activity. Hence, PTX3 restricts 
unwanted complement activation in the circulation (Nauta et al. 2003, Kunes et al. 
2012). Furthermore, ligand binding of PTX3 may prevent AP amplification via the 
recruitment of the complement regulators FH (Deban et al. 2008) and C4BP 
(Braunschweig et al. 2011) to the surface of apoptotic cells, thus facilitating 
phagocytosis of pathogens and clearance of cellular debris without the unnecessary 
activation of the terminal pathway (Inforzato et al. 2013). CRP also has the ability to 
activate the complement system. The native form of CRP however, may only attach to 
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membrane-bound C1q (Biro et al. 2007) with concomitant restrain of the terminal 
pathway (Thiele et al. 2014). Nevertheless, localized dissociation of pentameric CRP, 
induced by binding to cell-membrane phosphatidylcholine, allows for the excessive 
activation of the CP both in vitro and in vivo (Biro et al. 2007, Thiele et al. 2014). 
Parallel to complement activation, CRP may also regulate the CP and AP via 
recruitment of C4BP, FH, but also properdin (Sjoberg et al. 2006, Biro et al. 2007, 
O'Flynn et al. 2016). 
Even though there are differences in their production and specific activities, the 
expression of both pentraxins is induced in inflammatory conditions. Ligand-bound 
pentraxins were shown to initiate as well as regulate all three pathways of complement 
in vitro, while their ligand binding provides basis for cross-talk between the individual 
pathways (Garred et al. 2016). However, in vivo studies reported inconclusive data on 
the overall impact of PTX3 on tissue injury and recovery (Souza et al. 2002, Salio et al. 
2008, Souza et al. 2009, Lech et al. 2013) and no study has been designed so far to 
explore changes in the systemic level of pentraxins in relation to complement 
















Figure 1. Interaction of pentraxins with the complement system 
A sketch of the complement activation pathways and the interaction of pentraxin-3 
(yellow sphere) and C-reactive protein (blue sphere) with complement activator and 
regulator proteins is displayed based on the publication of Daigo et al. 2016 with 
modifications. (AP= alternative pathway, CP= classical pathway, LP= lectin pathway, 
MBL= mannose-binding lectin) 
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2.1.6. Dysregulation of the complement alternative pathway 
The proper control of AP activation requires a delicate regulatory mechanism, 
impairment of which can easily lead to complement dysregulation and disease 
pathogenesis. Dysregulation of the AP may originate from either the drop-out of restrain 
mechanisms, or from the hyperfunction of complement activators. Reduction of 
complement regulatory mechanisms may be caused by the dysfunction of the 
complement regulator proteins or may be attributed to factor consumption secondary to 
overactivation of the complement system. 
Primary mechanisms that lead to the dysregulation of the complement AP include 
impaired protease activity of FI with or without cofactor dysfunction, reduction of 
decay mechanisms or increased stability and half-life of the AP C3 convertase. These 
impairments may be attributed to either genetic mutations in the complement genes 
causing a quantitative or functional deficiency (or excessive activity) of the expressed 
protein, or complement factor blockade and complex stabilization by autoantibodies, all 
of which may induce the manifestation of complement-mediated diseases (Baines et al. 
2017). In recent years, deficiencies in complement regulatory processes associated to 
alterations of the complement genes or autoimmune mechanisms have been described in 
an increasing number of conditions (Wong et al. 2018). 
Dysfunction of FI leads to reduced C3b and C4b cleavage and thus prolongs the 
inactivation of both the AP and CP C3 convertases, leading to the dysregulation of the 
AP and CP in the fluid as well as in the solid phases. Whereas genetic mutations in the 
CFI gene have been linked to disease pathogenesis in atypical hemolytic uremic 
syndrome (aHUS), autoantibodies against FI were only demonstrated to have a minor 
contribution to the dysregulation of fluid and solid phase complement regulation, 
suggesting that their detection is rather an epiphenomenon than a pathogenic factor of 
disease manifestation (Kavanagh et al. 2012, Kavanagh et al. 2013). 
Mutations may also impair the cofactor activity of multiple complement regulator 
proteins, thus playing a major role in the pathogenesis of complement-mediated 
diseases. Pathogenic mutations identified in CFH (the most frequently detected genetic 
alteration in aHUS patients) (Noris et al. 2010, Fremeaux-Bacchi et al. 2013) are 
usually heterozygous point mutations that cluster at the C-terminal end of the protein. 
Hence, they interfere with the membrane-associated regulatory mechanisms and host-
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surface discrimination of FH without a quantitative deficiency in the circulatory levels 
of the protein (Kavanagh et al. 2013). Functional assays have shown that expression of 
the mutant protein causes a varying degree of impairment in the recognition and binding 
of heparin and C3b on e.g. endothelial cells and platelets, with subsequent cellular 
damage and the activation of thrombocytes (Vaziri-Sani et al. 2006, Abarrategui-
Garrido et al. 2008, Stahl et al. 2008, Ferreira et al. 2009). Mutations located at the N-
terminal regulatory regions of FH, even though are detected less frequently, cause a 
deficiency of AP regulation both in the fluid and solid phases (Pechtl et al. 2011). In 
addition to pathogenic point mutations, the regulatory functions of FH may also be 
altered due to genomic rearrangements in the RCA gene cluster that may yield hybrid 
genes of CFH and CFHRs, the genes encoding its related proteins (Factor H-related 
proteins 1-5, FHRs, respectively). Albeit the exact role of FHRs in complement 
dysregulation remains to date uncertain, mutations in CFHR5 have been associated with 
disease manifestation in multiple independent cohorts of aHUS and C3 glomerulopathy 
(C3G) patients (Monteferrante et al. 2007, Maga et al. 2010, Westra et al. 2012, Wong 
et al. 2018). Autoantibodies against FH have also been described in 4-14% of aHUS 
patients and 11% of C3G patients, and functional characterization of these antibodies 
has proven their causative role AP dysregulation and disease pathogenesis, discussed in 
detail below (Goodship et al. 2012, Zhang et al. 2012, Kavanagh et al. 2013) 
Similarly to CFI, mutations affecting CD46, the gene encoding MCP contribute to the 
dysregulation of both the AP and CP, since under physiological conditions MCP may 
engage both C3b and C4b. Unlike most of the CFH mutations however, about 75% of 
the alterations found in CD46 cause a reduced expression of the protein, thus 
contributing to altered regulation of complement (Kavanagh et al. 2013). In the presence 
of mutations in the THBD gene, THBD also loses its cofactor activity in the FI-
mediated cleavage of C3b, which has been linked to the manifestation of aHUS (Wong 
et al. 2018). 
Mutations the C3 and CFB genes on the other hand belong to the activating mutations 
of complement. These mutations were reported to either cause altered binding of 
regulators (e.g. MCP) or an enhanced formation of the AP C3 convertase that is more 
resistant to decay due to a stronger bond between FB and C3b (Kavanagh et al. 2013). 
This leads to increased complement deposition on cellular surfaces and the disruption of 
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the balance between amplification and regulation (Harrison 2018). However, mutations 
of C3 have also been described to cause reduced secretion of the protein, the role of 
which in AP dysregulation and disease pathogenesis remains to date unrevealed 
(Kavanagh et al. 2013). Increased convertase stability and activity have also been 
associated with the presence of anti-C3b and anti-FB antibodies (Strobel et al. 2010, 
Chen et al. 2011, Marinozzi et al. 2017) as well as the production of a C3bBb stabilizing 
IgG, the C3 Nephritic Factor (C3Nef) (Daha et al. 1976, Daha et al. 1977). 
In addition to germline genetic mutations, enhanced AP C3 convertase activity and 
MAC formation may also be attributed to somatic mutations in the phosphatidylinositol 
glycan anchor biosynthesis class A (PIGA) gene. The PIGA gene encodes a glycosyl 
transferase, alterations of which cause clonal deficiency of GPI-anchored proteins 
including DAF and CD59. Their dysfunction causes dysregulation of complement 
activity on the surface of red blood cells, clinically manifesting in paroxysmal nocturnal 
hemoglobinuria, characterized by chronic hemolysis with acute paroxysms and an 
increased risk of thrombus formation (Baines et al. 2017). 
Despite adequate functional evidence on the contribution of the above genetic 
alterations and autoimmune mechanisms to complement dysregulation, fundamental 
questions regarding the clinical manifestation of complement mediated diseases remain 
to date unrevealed. Multiple facts e.g. incomplete penetrance of the genetic alterations, 
presence of autoantibodies in disease remission and disease manifestation in adulthood 
suggest that an additional, yet undiscovered trigger event is required to set off the self-
amplifying mechanism of AP dysregulation. Furthermore, despite the accumulated 
knowledge on the structure-function relationships of genetic alterations, to date we still 
have no definitive explanation for the association of certain mutations to one clinical 
condition rather than another (Pechtl et al. 2011). Therefore further molecular as well as 
clinical investigations are required to challenge these controversies and to fill the gaps 




2.2. Thrombotic microangiopathies 
2.2.1. Classification and pathogenesis of thrombotic microangiopathies 
Thrombotic microangiopathies (TMA) are rare but life-threatening disorders 
characterized by microangiopathic hemolytic anemia and acute thrombocytopenia with 
or without organ impairment (e.g. signs of neurological or kidney injury). The bed-side 
diagnosis of TMAs is based on this triad of clinical symptoms and routine laboratory 
results, however, intensive research of the recent decades revealed that TMAs cover 
distinct subgroups of diseases. Their etiology-based classification discriminates between 
acquired or inherited primary TMAs with known molecular etiology, secondary TMAs 
as complication of underlying diseases or conditions, and specific infection-associated 
TMAs. TMAs are severe conditions that require immediate attention and diagnostic 
workup for complement abnormalities. Their expeditious differential diagnostics is 
especially important, since the identification of the exact subgroup of TMA has an 
impact on the determination of the optimal therapeutic choice immediately from the 
onset of the acute phase. 
2.2.2. Thrombotic thrombocytopenic purpura 
Thrombotic thrombocytopenic purpura (TTP), covers a TMA subgroups, where beyond 
the clinical and laboratory triad of TMA, patients usually present with critical 
thrombocytopenia (as low as 4-5G/L) and neurological symptoms, whereas signs of 
kidney injury are less frequent clinical features of disease. This form of TMA is caused 
by the deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 
motif member 13 (ADAMTS13), either due to its blockade by antibodies or mutations 
in the ADAMTS13 gene. Under physiological conditions this enzyme cleaves the ultra-
large form of von Willebrand Factor (ULVWF), which is secreted by activated 
endothelial cells, and can spontaneously bind and activate platelets, thus contributing to 
thrombus formation at the site of activation. Although ADAMTS13 deficiency is 
accountable for TTP, it may also be present in disease remission, which supports the 
hypothesis that the onset of TTP requires a trigger event (such as pregnancy or 
infections), which leads to endothelial activation and therefore an enhanced expression 




2.2.3. Typical hemolytic uremic syndrome 
Hemolytic uremic syndrome (HUS) on the other hand covers distinct forms of primary 
TMAs, which usually present with the triad of hemolytic anemia, thrombocytopenia and 
acute renal failure, while neurologic symptoms have only been reported in a minority of 
patients. In about 90% of the cases, HUS is caused by Shiga toxin-producing 
Escherichia coli (STEC), defined as typical or STEC-HUS (Wong et al. 2018) that 
represents the most frequent cause of acute kidney failure in children. It is induced by a 
gastrointestinal infection, where Shiga-toxin (Stx) is released to the circulation from 
mucus-adhered bacteria and causes microangiopathy through the blockade of protein 
synthesis and subsequent activation of the endothelial cells, red blood cells and platelets 
(Karpman et al. 2006, Orth-Holler et al. 2014, Arvidsson et al. 2015, Jokiranta 2017).  
2.2.4. Atypical hemolytic uremic syndrome 
Atypical HUS on the other hand represents a rare form of TMA (Fakhouri et al. 2017) 
with an incidence rate of approximately 0.23-0.42 per 106 per year (Fakhouri et al. 
2017). Atypical HUS is mediated by the dysregulation of the AP, evoked either by 
pathogenic mutations in the complement genes or by the presence of autoantibodies 
directed against the complement regulator FH (discussed in detail below). Mutation 
associated forms of aHUS usually manifest in either very early childhood, often in 
infants younger than 1 year of age, or in women at the postpartum period, whereas 
autoimmune aHUS is a disease of adolescence. Atypical HUS has a relapsing-remitting 
disease course and therefore requires long-term patient management. Just like in the 
case of STEC-HUS, prodromal symptoms of aHUS may include gastrointestinal 
complaints and signs that could be misleading at the initial presentation. However, since 
the endothelial injury in aHUS is caused by the dysregulation of the AP, detection of 
laboratory signs of complement AP consumption may aid the differential diagnostics of 
aHUS together with the lack of proof for an STEC infection and clinical improvement 
of patients. Definite diagnosis of aHUS however, requires the functional and genetic 
testing of the patients’ complement profile that reveals the underlying molecular 
mechanism of disease pathogenesis in nearly two third of the cases. Likely pathogenic 
mutations are identified by 50-60% of aHUS patients, with a combination of mutations 
identified in 10-25% of the cases (Kavanagh et al. 2013). Approximately 25% of the 
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pathogenic mutations are found in the CFH gene (Noris et al. 2010, Fremeaux-Bacchi et 
al. 2013), whereas in addition to mutations in the complement genes, genetic alterations 
of THBD and diacylglycerol kinase epsilon (DGKE) have been associated with aHUS, 
too (Delvaeye et al. 2009, Lemaire et al. 2013, Azukaitis et al. 2017). Along likely 
pathogenic mutations that have established functional consequences, haplotypes and a 
multitude of variations with an unknown significance have been linked to an increased 
risk of aHUS development. Even though these have not been shown to directly 
contribute to disease pathogenesis, in combination with other trigger mechanisms they 
might induce the manifestation of disease. 
Unlike the genetically determined forms, autoimmune aHUS usually manifests in older 
children and adolescents following a preceding minor infection of the respiratory or 
gastrointestinal tracts (Dragon-Durey et al. 2010). It accounts for 4-14% of all aHUS 
cases (Skerka et al. 2009, Hofer et al. 2013, Kavanagh et al. 2013, Nester et al. 2015), 
although an Indian cohort reported an incidence rate of 56% with an unexplained reason 
behind the high frequency of autoantibody positivity (Sinha et al. 2014). Autoimmune 
aHUS has a high relapse rate with the risk of developing end stage renal disease (Noris 
et al. 2009, Dragon-Durey et al. 2010, Dragon-Durey et al. 2010, Noris et al. 2015). 
Laboratory diagnostics of autoimmune aHUS involve the detection of anti-Factor H 
(anti-FH) antibodies that often goes together with low levels of FH due to immune 
complex formation (Blanc et al. 2012), the levels of which were shown to correlate with 
disease severity (Blanc et al. 2012). Further characteristic laboratory findings in 
autoimmune aHUS are low C3 and FB levels indicative of the overactivation and 
subsequent factor consumption of the AP (Blanc et al. 2012), frequently accompanied 
by a decreased activity or deficiency in the whole complement AP activity. The genetic 
linkage of autoimmune aHUS to deficiency of CFHR1 justifies testing for copy number 
variations in the CFHR genes via multiplex ligation-dependent probe amplification 
(MLPA) analysis. However, a negative finding in this regard does not exclude the 
presence of autoimmune aHUS, since the lack of CFHR1 is not a prerequisite for the 
development of autoantibodies, indicated by a considerable proportion of autoimmune 
aHUS patients with no genetic alterations in the CFHR genes (Dragon-Durey et al. 




2.2.5. Secondary thrombotic microangiopathies 
Secondary forms of TMA encompass a heterogeneous group of disorders all of which 
are evoked by the progression of a preexisting condition. Secondary TMA may be 
associated among others with glomerular diseases, severe infections and septic 
conditions, allogenic hematopoietic stem cell or solid organ transplantation, systemic 
autoimmune diseases, pregnancy, tumor progression and antitumor therapy as well as 
malignant hypertension. Despite their distinct etiologies, shared features of secondary 
TMAs include decreased ADAMTS13 activity and overactivation of multiple 
complement pathways, leading to laboratory signs of complement consumption. 
2.2.6. Pathological complement activation in thrombotic microangiopathies 
Endothelial damage and subsequent microvascular thrombosis are key pathogenic 
factors in TMA. Albeit traditionally aHUS was recognized as a TMA form mediated by 
complement dysregulation, by now vascular injury has been associated with 
complement overactivation in all etiological forms of this disease (Table 1) (Noris et al. 
2012, Reti et al. 2012, Baines et al. 2017, Farkas et al. 2017). 
A shared characteristic of the coagulation and complement cascades is their initial 
activation at local sites of infection or tissue injury (Baines et al. 2017). There is a 
considerable interaction between the activator mechanisms of both cascades 
(Oikonomopoulou et al. 2012, Kenawy et al. 2015, Foley 2016), provided by the diverse 
ligand binding capacity of certain PRMs and activation enzymes of complement (Bossi 
et al. 2011, Takahashi et al. 2011, La Bonte et al. 2012), augmented by complement 
activation through thrombin and additional coagulation factors (Huber-Lang et al. 2006, 
Amara et al. 2010, Krisinger et al. 2012, Berends et al. 2014). Components of each 
system may cleave and activate one another (Baines et al. 2017), thus providing 
molecular basis for the joint manifestation of pathological thrombosis and complement 
overactivation in distinct etiological forms of TMA (Noris et al. 2012, Reti et al. 2012, 
Baines et al. 2017, Farkas et al. 2017). 
Atypical HUS is a prototypic disease of AP dysregulation attributed to the above 
discussed genetic alterations of complement components and autoimmune mechanisms 
(Wong et al. 2018). STEC-HUS on the other hand is primarily not a complement-
mediated disorder. Nevertheless, increased levels of complement degradation products 
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(C3a(desArg) and C3d), Bb and the properdin-stabilized AP C3 convertase (C3bBbP) 
together with the elevation of sC5b-9 have been detected in the circulation of STEC-
HUS patients (Thurman et al. 2009, Stahl et al. 2011, Westra et al. 2017), indicative of 
complement overactivation in the acute phase of disease. Intensified complement 
activity in STEC-HUS is supposedly due to the combined effect of Stx and bacterial 
lipopolysaccharide (LPS) on complement activation and coagulation (Stahl et al. 2011, 
Arvidsson et al. 2015), a hypothesis corroborated by independent in vitro ad in vivo 
observations. Inter alia, Stx was shown to activate the AP in the fluid phase and to 
interfere with the regulatory activity of FH on cellular surfaces (Orth et al. 2009), 
together with the upregulation of P-selectin on microvascular endothelium, thus 
promoting C3b deposition and thrombus formation (Morigi et al. 2011). Stx together 
with LPS was also reported to induce the formation of platelet-leukocyte aggregates in 
vitro (Stahl et al. 2011, Arvidsson et al. 2015), whereas the combined thrombotic effects 
of Stx and LPS could be diminished by the admission of a C3a receptor antagonist or by 
the application of FB-deficient mice in animal models of STEC-HUS in vivo (Morigi et 
al. 2011). 
Increased complement activation product levels together with an elevated cytokine 
response have also been reported in TTP (Reti et al. 2012, Westwood et al. 2014). 
Increased complement activity has been detected at both the acute presentation and in 
remission of TTP, the extent of which was reported to be associated with the level of 
anti-ADAMTS13 antibodies in the autoimmune form of this disease (Reti et al. 2012, 
Westwood et al. 2014). The underlying mechanism of the sustained complement 
response in TTP could be attributed to multiple mechanisms participating in disease 
pathogenesis. On the one hand, increased expression of P-selectin on activated platelets 
and endothelial cells may lead to an enhanced C3b deposition and thus substantiate 
complement activation on the tagged endothelial surface (Del Conde et al. 2005). On 
the other hand, ULVWF may also initiate the AP and the terminal pathway of 
complement via direct binding of complement factors (Bettoni et al. 2017). Enhanced 
generation of the complement activation products C3a, C5a, and sC5b-9 may in turn 
lead to further activation of endothelial cells with inherently increased ULVWF and P-
selectin expression as well as decreased THBD expression, ultimately causing the 
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uncontrolled activation of coagulation and the dysregulation of complement (Bettoni et 
al. 2017). 
Despite the many different etiologies of secondary TMA, overactivation and subsequent 
consumption of both the CP and AP have been described in this condition, too (Farkas 
et al. 2017). Elevated systemic levels of sC5b-9 and C3a have been associated with poor 
long-term outcome in independent cohorts of secondary TMA patients (Jodele et al. 
2013, Farkas et al. 2017, Wong et al. 2018). Although dysregulation of the AP is not a 
distinguished mediator of disease pathogenesis in secondary TMA, its involvement has 
been recently suggested in the development of hematopoietic stem cell transplantation-
associated TMA, that could be attributed to chemotherapy, radiation, and infection-
induced endothelial injury and neutrophil cell activation (Jodele et al. 2013, Yuen et al. 
2016, Gloude et al. 2017, Wong et al. 2018). 
In conclusion, the acute phase of TMAs are accompanied by complement dysregulation 
or consumption, and an overdrawn inflammatory response. This may induce among 
others the production of inflammatory proteins, such as CRP and PTX3. Based on the 
reported complement regulatory activity of pentraxins, the released proteins could 
interfere with local complement activity at the site of vascular injury (Jaillon et al. 
2007). However, so far only in vitro studies have been published in this regard, whereas 
no investigation involving human subjects has explored the systemic levels of 
pentraxins in the acute phase of TMA or the in vivo relation of PTX3 and CRP to 
complement activity. 
Table 1. Role of complement in thrombotic microangiopathies 
Distinct forms of thrombotic microangiopathies (TMA) are displayed, grouped based-
on the most important, common pathogenic factors and the role of complement in each 
subgroup of disease. (ADAMTS13 = a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif member 13, ADAMTS13 = the gene encoding 
ADAMTS13, aHUS = atypical hemolytic uremic syndrome, AP = alternative pathway, 
CP = classical pathway, DGKE = diacylglycerol kinase epsilon, IgM = Immunoglobulin 
M, MMACHC-TMA = thrombotic microangiopathy associated to methylmalonic 
aciduria and homocystinuria, cblC complementation type, MMACHC = the gene 
encoding methylmalonic aciduria and homocystinuria type C protein, STEC-HUS = 
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Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome, Stx = 
Shiga-toxin, TTP = thrombotic thrombocytopenic purpura) 
TMA subgroup Key pathogenic factors Role of complement in the pathogenesis 
Inherited primary TMA 
Complement-mediated 
aHUS 
-Endothelial damage due to 
severe dysregulation of the 
complement AP 
-Genetic alteration in the complement genes 
and subsequently altered expression or 
function of their encoded proteins 
DGKE-aHUS 
-Prothrombotic state on the 
endothelium due to the loss of 
DGKE function 
-Enhanced terminal pathway activation and 
therefore increased sC5b-9 levels that may 
alter podocyte metabolic pathways, the 
structure and function of the extracellular 
matrix, membrane lipids and key proteins of 
the cytoskeleton and the slit-diaphragm 
MMACHC-TMA 
-Impaired intracellular vitamin 
B12 metabolism due to 






-Congenital deficiency of the 
ADATMS13 metalloproteinase 
due to mutations in the 
ADATMS13 gene 
-C3b binding and complement activation 
through activated endothelial cells and 
platelets 
-Direct activation of the complement AP by 
the ULVWF 
Acquired primary TMA 
Autoimmune aHUS 
-Endothelial damage due to 
severe dysregulation of the 
complement AP 
-Dysfunction of the complement regulator 
Factor H due to autoantibodies 
Acquired TTP 
-Inhibitory antibodies that 
block the ADATMS13 
metalloproteinase 
-C3b binding and complement activation 
through activated endothelial cells and 
platelets 




-Endothelial damage caused by 
the binding and internalization 
of Stx 
-Complement activation through Stx and 
LPS 
-Increased C3b binding to the endothelium 





-Neuraminidase production and 
cleavage of N-acetylneuraminic 
acid from glycoproteins on the 
cell membrane of erythrocytes, 
platelets, glomeruli and 
hepatocytes, exposure of the 
Thomsen–Friedenreich antigen 
-Interaction of the Thomsen–Friedenreich 
antigen with preformed IgM initiates 
excessive complement activation of both the 
CP and AP 
Secondary forms of TMA 
Secondary TMA 
-Worsening of a known 
preexisting condition and 
subsequent coagulopathy with 
tissue or organ damage 
involving the endothelium 
-Dysregulation of both the CP and AP with 





2.2.7. Alternative pathway dysregulation associated with anti-Factor H antibodies 
in atypical hemolytic uremic syndrome 
Anti-FH antibodies in aHUS have first been reported in a French patient cohort in 2005 
(Dragon-Durey et al. 2005), and since then multiple independent investigations have 
shown their functional relevance in disease pathogenesis. Upon binding to FH, 
autoantibodies interfere with the complement regulatory activity on the surface of host 
cells that leads to overactivation of the complement AP and subsequent complement-
mediated tissue damage. The majority of the anti-FH antibodies belongs to the IgG 
subclass, although some patients have been reported to develop IgA antibodies, too 
(Strobel et al. 2011). Albeit the antibodies may recognize multiple domains on FH 
(Moore et al. 2010, Blanc et al. 2012), epitope mapping using recombinant FH 
fragments have shown that most of the antibody binding epitopes cluster on the C-
terminal SCRs of FH (Jozsi et al. 2007, Jozsi et al. 2008, Moore et al. 2010, 
Bhattacharjee et al. 2015). The antibody binding site was reported to overlap with that 
of C3b and cellular ligands, which explains why anti-FH antibodies inhibit the binding 
of C3b and its degradation products thus reducing the cofactor and decay accelerating 
activities of FH. Furthermore, antibody binding perturbs the FH-mediated cell-
protection, shown by increased hemolysis of red blood cells in the presence of patient 
IgG (Jozsi et al. 2007, Blanc et al. 2012). Anti-FH antibodies have also been described 
in C3G, however their functional characteristics were reported to be substantially 
different from those identified in aHUS patients (Blanc et al. 2015). Whereas the 
functional consequence of the antibody binding to FH is widely studied and 
comprehensive knowledge has been accumulated in regard to the structural exploration 
of antibody binding to the folded FH domains, detailed structural analysis of where the 
aHUS-associated FH epitopes are localized at the amino acid level are still lacking. 
Furthermore, the immediate trigger that would evoke autoantibody production against 
FH has not yet been identified. Nevertheless, since a mild infection is often recorded 
prior to the manifestation of aHUS, the higher prevalence of gastrointestinal pathogens 
(Togarsimalemath et al. 2018) together with the genetic linkage of the disease (e.g. 
deficiency of FHR-1) have been proposed to contribute to the pathological activation of 




2.2.8. Factor H-related proteins and their genetic-linkage to anti-Factor H 
antibodies 
Alongside with FH, there are six additional members of the FH protein family: FHL-1 
and the FHRs 1-5 (Figure 2). FHL-1 is a splice variant derived from the CFH gene, 
whereas FHRs evolved from FH via non-allelic homologous recombination (Jozsi et al. 
2014). As a result of this, all members of the FH protein family are composed of SCR 
domains that share a high sequence homology to each other. Corresponding to their 
structural similarities, FHL-1 and FHRs were reported to participate in the regulation or 
sometimes de-regulation of complement activity through multiple mechanisms. FHL-1 
carries a unique four amino acid long C-terminus, a so called SFTL tail corresponding 
to its components: serine, phenylalanine, threonine and leucine (Perez-Caballero et al. 
2000), but the rest of the protein is identical to the first 7 SCR domains of FH 
(Schwaeble et al. 1987). Therefore, FHL-1 shares functional similarities to FH 
including complement inhibition through C3b binding (Kuhn et al. 1995) and the 
recognition of common ligands such as pentraxins and malondialdehyde epitopes 
(Sanchez-Corral et al. 2018). However, apparent contrasts in the conformation of the 
two proteins and the presence of the C-terminal tail on FHL-1 contribute to considerable 
differences in the ligand interactions of the two proteins (Sanchez-Corral et al. 2018). 
FHRs on the other hand do not carry all the four N-terminal regulatory domains of FH, 
therefore they have no or only residual cofactor and decay accelerating activities in the 
regulation of the complement AP. However, their reported binding of C3b and other 
deposited fragments of C3 (iC3b and C3d) (Goicoechea de Jorge et al. 2013) via their 
C-terminal domains may induce competition with FH for the C3 binding site, a process 
referred to as complement de-regulation (Sanchez-Corral et al. 2018). Additional ligand 
binding similarities include the recognition of host surface ligands and ECM 
components (Blackmore et al. 1998, Hellwage et al. 1999, McRae et al. 2005, Heinen et 
al. 2009, Strobel et al. 2011, Csincsi et al. 2015, Rudnick et al. 2018) as well as 
recruitment of FHRs to apoptotic and necrotic cells via surface-bound PRMs (e.g. 
pentraxins), where in contrast to FH some FHRs have been reported to enhance the 
activation of not only the alternative but also the classical pathways of complement 
(Mihlan et al. 2009, Hebecker et al. 2010, Hebecker et al. 2012, Csincsi et al. 2015, 
Csincsi et al. 2017, Rudnick et al. 2018). However, given the relatively low 
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concentration of FHRs and their lower avidity for C3b binding compared to that of FH 
(Sanchez-Corral et al. 2018), the complement activator effect of FHRs may be 
insignificant in the physiological regulation of the AP. 
Under pathological AP activation however, locally increased levels and activity of 
FHRs may contribute to disease pathogenesis. Numerous reports have described the 
association of genetic alterations in CFHRs to complement-mediated diseases (Hughes 
et al. 2006, Gharavi et al. 2011, Sanchez-Corral et al. 2018). The autoimmune form of 
aHUS is linked to the deficiency of CFHR1 and -3 that covers the homozygous deletion 
of an 80 kb-long genomic region in 82-88% of patients with FH autoantibodies (Zipfel 
et al. 2007, Jozsi et al. 2008, Dragon-Durey et al. 2010, Geerdink et al. 2012, Hofer et 
al. 2013). Conversely, the frequency of the heterozygous deletion of CFHR1 is similar 
in healthy individuals and aHUS patients. 
FHR1 shares a high sequence homology with FH. The C-terminal SCRs of the two 
proteins differ in only two amino acids, namely FH carries a serine at amino acid 
position 1191 and a valine at position 1197, while FHR1 contains a leucine and an 
alanine at the corresponding positions (residue 290 and 296), whereas FHR1 domain 4 
and FH domain 19 are identical to one another (Abarrategui-Garrido et al. 2009). FHR1 
was shown not only to compete with FH in C3b binding (Goicoechea de Jorge et al. 
2013), but also to cross react with anti-FH antibodies and to neutralize the antibody-
associated enhanced red blood cell lysis in vitro (Strobel et al. 2011, Bhattacharjee et al. 
2015). These functional studies together with the high sequence homology of the C-
terminal domains of FH and FHR1 suggest an overlap of the antibody binding sites on 
the two proteins. Genetic and structural analyses have pointed out CFHR1 deficiency as 
a potential predisposing factor for the development of autoimmune aHUS (Kavanagh et 
al. 2013, Bhattacharjee et al. 2015) and anti-FH binding of the folded FH and FHR1 C-
terminal domains have recently been compared (Bhattacharjee et al. 2015), however no 
investigation aimed to date for the localization of the antibody binding epitopes on FH 
as well as FHR1 on the amino acid level, which however, could provide a direct 



















Figure 2. Homology between Factor H and the Factor H related proteins 
Illustration of Factor H (FH) and its related proteins (FHRs) based on the publication of 
Sanchez-Corral et al. 2018 with modifications. The proteins are displayed with the 
sketch of their short consensus repeat (SCR) domains indicated by numbers. SCR 
domains of the FHRs are aligned vertically to their homologous domains in FH. Ligand 
binding sites and functional characteristics of FH are indicated above the schematic 
pictures of the FH domains. (C3b = complement component 3b, C3d = complement 
component 3d, CRP = C-reactive protein, FHR1-5 = Factor H-related proteins 1-5, 
PTX3 = pentraxin-3) 
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3. SPECIFIC AIMS 
3.1. Analysis of the association between systemic pentraxin levels and laboratory 
signs of disease activity in thrombotic microangiopathies 
Albeit both PTX3 and CRP have been described to regulate complement activation in 
vitro (Csincsi et al. 2015), no study has been designed so far to explore changes in the 
systemic level of pentraxins in complement mediated diseases, such as TMAs, in vivo. 
Therefore we performed a case control study to determine the systemic levels of PTX3 
and CRP in patients at the acute phase as well as remission of TMA. We analyzed the 
relationship between the systemic level of pentraxins and TMA etiology, the clinical 
outcome of patients and classical laboratory markers of TMA. 
3.2. Investigation of the relation of complement overactivation and systemic 
pentraxin levels in distinct forms of thrombotic microangiopathies 
In distinct etiological groups of TMAs including aHUS, STEC-HUS, secondary TMA 
and TTP we further investigated the relation of systemic pentraxin levels to laboratory 
signs of complement overactivation and consumption in the acute phase of disease. We 
determined the patients’ complement factor levels, the whole complement CP and AP 
activities and the systemic levels of complement activation products to reveal any 
potential association between complement overactivation and the systemic levels of 
PTX3 and CRP in the acute phase and remission of TMA, as well as in the distinct 
subgroups of disease. Furthermore we determined the effect of excess PTX3 on the AP 
activity in vitro to explore the role of PTX3 release in the pathogenesis of TMA. 
3.3. Epitope analysis of anti-Factor H antibodies in atypical hemolytic uremic 
syndrome 
Antibody binding to FH induces loss of host cell recognition and dysregulation of the 
complement AP (Kavanagh et al. 2013). The functional consequence of the FH-
antibody interaction has been widely studied, however little is known about the 
structural basis of FH-blockade and the role of FHR proteins in disease pathogenesis. 
Based on recent observations (Bhattacharjee et al. 2015, Nozal et al. 2016) we 
hypothesized that the antibody binding site is located at the C-terminal domains of FH, 
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therefore we aimed for the structural characterization of antibody binding to FH SCR 
domains 19-20. To localize the aHUS-associated FH epitopes on the amino acid level, 
we performed fine epitope mapping of the complement regulator using point-mutated 
FH domains and linear epitope mapping with overlapping synthetic peptides. We 
further investigated whether aHUS specific linear epitopes are present on FHR1, based 
on its homology to FH and its described cross-reactivity with the anti-FH antibodies 




4.1. Patient selection, sample collection and study design 
4.1.1. Sample collection from patients at the acute phase of thrombotic 
microangiopathy 
171 TMA patients with acute disease flare were enrolled in the case-control study for 
the analysis of systemic pentraxin levels and complement consumption, whose blood 
samples were sent to our laboratory for differential diagnostic evaluation between 
November 2007 and October 2017. Acute phase serum and plasma samples from all 
enrolled subjects were collected prior to the start of plasma exchange therapy, however 
in some cases (N=16) fresh frozen plasma (FFP) had been administered to the patients 
prior to sampling. Diagnosis of TMA was established based on laboratory signs of 
microangiopathic hemolytic anemia, thrombocytopenia (<150 G/L) and clinical or 
laboratory signs of organ damage. Patients were included in the study only if all of the 
above criteria were met. For stratification of TMA patients by disease etiology the 
following groups were formed (Figure 3): (1) STEC-HUS (N=34): acute gastroenteritis 
and signs of acute kidney injury with proof of Shiga like-toxin producing Escherichia 
coli infection, (2) TTP (N=30): ADAMTS13 deficiency (activity below 10%) with the 
presence of ADAMTS13 inhibitors, (3) aHUS (N=44): HUS with presence of anti-FH 
autoantibodies, or HUS with identified pathogenic or likely pathogenic variations in the 
complement genes (CFH, CFHR5, CFI, CD46, C3, CFB), THBD or DGKE, or HUS 
cases without identified likely pathogenic rare variations in these genes, (4) secondary 
TMA (N=63): evidence of coexisting disease including malignancy, autoimmune 
disease, sepsis, solid organ transplantation, open heart surgery or malignant 
hypertension. Exclusion criteria were ongoing plasma exchange or complement 
inhibitory therapy at the time of sample collection (during the first acute flare), or the 
lack of available blood sample. Genetic analysis was performed by direct DNA 
sequencing of polymerase chain reaction products amplified from total genomic DNA. 
Pathogenic and likely pathogenic mutations were defined based on published literature 
data and included mutations either described previously in aHUS patients or expected to 
cause aHUS based on functional analysis reported in literature. Data on the clinical 
course, blood count and chemistry were collected from the medical charts. Acute kidney 
DOI:10.14753/SE.2020.2318
39 
injury was defined as documented oligo- or anuria or creatinine and carbamide levels 
above the upper limit of the laboratory normal range. Patients were followed-up after 
hospital discharge and outcome including mortality was registered. Follow-up samples 
were available for aHUS (N=31, 15-month median time interval between sampling) and 
TTP (N=19, 8-month median time interval between sampling) patients in remission. 
Whole blood samples were immediately separated after collection (to yield serum, 
EDTA-anticoagulated plasma, and sodium-citrate-anticoagulated plasma) and stored in 
aliquots at 70oC until further analysis. For appropriate comparison age- and sex-
matched healthy individuals were selected, none of whom showed clinical or laboratory 
signs of TMA or an acute phase reaction that could have influenced the measured 
laboratory parameters. This study was carried out in conformity with the Helsinki 
Declaration. Written informed consent was obtained from all participants, and the study 














Figure 3. Stratification of TMA patients based on disease etiology 
Confirmed disease etiology of the TMA patients enrolled in the case-control study for 
the analysis of the systemic pentraxin levels in the acute phase of TMA. Number of 
participants (N) is shown as proportion of a whole. (HUS=hemolytic uremic syndrome, 
STEC-HUS=Shiga-like toxin-associated hemolytic uremic syndrome, TMA=thrombotic 
microangiopathy, TTP=thrombotic thrombocytopenic purpura, Tx=transplantation) 
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4.1.2. Sample collection from autoimmune atypical hemolytic uremic syndrome 
patients 
For linear epitope mapping sera of children in the acute phase of aHUS were used, from 
whom a sample was obtained prior to the start of plasmapheresis. Inclusion criteria were 
as follows: diagnosis of HUS based on the presence of microangiopathic hemolytic 
anemia, thrombocytopenia (<150G/L) and renal injury, with an anti-FH antibody level 
over 110 AU/mL (Dragon-Durey et al. 2010). Exclusion criteria included aHUS in 
remission or active therapy with either plasmapheresis, corticosteroids, 
cyclophosphamide or rituximab as well as the lack of available serum sample. 
Altogether eight patients were enrolled in this investigation, seven of which had an 
available remission phase serum sample (Figure 4). Remission phase sample collection 
was performed 6-12 months after the termination of any specific treatment of the 
subjects. Patient enrollment was closed in September 2016. Control sera samples were 
obtained from leftover serum specimens from children (median age of 9 years) admitted 
to the 1st Department of Pediatrics at Semmelweis University upon distinct indications, 
by whom a detailed laboratory analysis (including inflammatory markers) did not reveal 
any pathological findings. All control children were negative (below cutoff) for anti-FH 
antibodies. This study was carried out in accordance with the Helsinki Declaration. The 
study was approved by the Ethics Committee on Human Research in Budapest (8361- 















Figure 4. Patient selection flow chart for the epitope analysis studies 
Nineteen patients with the diagnosis of atypical HUS (aHUS) who had a positive serum 
anti-Factor H antibody test result (>110 AU/ml) were identified in our laboratory during 
the study period. Patients with the first acute phase of aHUS, who had available sera 
samples taken prior to the initiation of plasma exchange therapy were included in our 
investigation. (aHUS = atypical hemolytic uremic syndrome, anti-FH antibody = anti-
Factor H antibody, PEX = plasma exchange therapy) 
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4.2. Determination of laboratory parameters in patients at the acute phase of 
thrombotic microangiopathy 
Complement activity-, component-, regulator-, and activation product determinations, 
CRP and PTX3 measurements were performed in our laboratory from the blood 
samples of acute phase-TMA patients. The AP activity was determined with the 
commercially available WIESLAB Alternative pathway ELISA kit (EuroDiagnostica, 
Malmö, Sweden) (Seelen et al. 2005), whereas total complement CP activity was 
assessed using the sheep-erythrocyte hemolytic titration test. CRP, C3 and C4 levels 
were measured by turbidimetry (Beckman Coulter, Brea, CA), while FB and FI were 
determined by radial immunodiffusion assay. The level of the complement regulators 
C1q and FH as well as the titer of the anti-FH antibody were measured using in house 
ELISA techniques, described in detail in our earlier publications or elsewhere 
(Delamarche et al. 1988, Reti et al. 2012). ADAMTS13 activity was evaluated by the 
application of the fluorogenic substrate FRETS-VWF73 (Reti et al. 2012). 
Commercially available kits were used to assess the levels of the complement activation 
products sC5b-9 and C3a (C3a-desArg) (Quidel, San Diego, CA, USA) and for the 
measurement of PTX3 (R&D systems Minneapolis, MN, USA). 
4.3. In vitro assessment of pentraxin-3 effect on alternative pathway activation 
In vitro effect of recombinant human PTX3 on AP activation was assessed using two 
assays. The AP hemolytic activity in the presence of excess PTX3 was determined with 
a modified C3Nef hemolytic assay, and the AP activity on LPS-coated ELISA plates 
was measured by the WIESLAB Alternative pathway ELISA kit (EuroDiagnostica, 
Malmö, Sweden). The C3Nef assay was performed on washed sheep erythrocytes, 
where patients’ samples were replaced by normal human serum (NHS) spiked with 
recombinant human PTX3 (R&D systems Minneapolis, MN, USA) in gradually 
decreasing concentrations. After a 20 minute incubation of PTX3 with NHS, the 
solution was added to sheep erythrocytes. The formation of the C3 convertase was 
allowed within a 10 minute incubation time at 30oC, and assembly of the terminal 
pathway MAC was achieved by the addition of undiluted rat serum to the cells and 
incubation at 37oC for 60 minutes. The extent of hemolysis was detected by reading the 
OD at 412 nm. The effect of PTX3 on the assembly of C5b-9 on a plastic surface was 
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assessed with the WIESLAB Alternative pathway ELISA. As in the hemolytic assay, 
patients’ sera were replaced by PTX3 spiked NHS, otherwise the assay was performed 
according to the manufacturer’s instructions. To allow comparison of data, the AP 
activities in each experiment were expressed as ratio of the reference (optical density of 
NHS with buffer control) in percentage. 
4.4. Determination of the anti-Factor H antibody levels 
Serum anti-FH IgG level was determined by an enzyme-linked immunosorbent assays 
(ELISA) as described previously (Dragon-Durey et al. 2005), with the following 
modifications applied: Nunc MaxiSorp plates (Nunc, Roskilde, Denmark) were coated 
with 1 g/ml purified human FH (Calbiochem, San Diego, CA, USA) overnight. 
Following blocking with 1% bovine serum albumin in phosphate-buffered saline (PBS), 
serum samples were added at a dilution of 1:200. As secondary antibody a rabbit anti-
human IgG-HRP was used (Dako, Glostrup, Denmark) and detection of bound IgG was 
performed by 3,3 ,5,5 -tetramethylbenzidine (TMB). Optical density (OD) was read at 
450 nm (reference at 620 nm). Calibration of the assay was completed with a sample 
obtained as a kind gift from Dr. Dragon-Durey, and the cutoff value (>110 AU/ml) was 
determined according to the mean + 2 times the standard deviation of the values of 80 
healthy individuals. 
4.5. Peptide synthesis for epitope mapping 
Fifteen amino acid-long peptides of FH SCR domains 19–20 and the FHR1 region 
homolog to the amino acid sequence 1177–1211 on FH (amino acids 276–310 of FHR1) 
were synthesized by Dr. Katalin Uray at Eötvös Loránd University Budapest, according 
to Geysen’s method (Geysen et al. 1984) with modification applied as described 
previously (Uray et al. 2003). Peptides overlapping by five amino acid residues were 
synthesized in duplicates on alanyl glycine functionalized polyethylene pins 
(Mimotopes NCP gears (Clayton, VIC, Australia)) with Fmoc/tBu chemistry. We used 
tBu (Thr, Ser, Tyr), OtBu (Asp, Glu), Acm (Cys), Pmc (Arg) and Boc (His, Lys) as 
side chain protecting groups. The N -Fmoc amino protecting group was removed 
with 2% piperidine/ 2% 1,8-diazabicyclo(5.4.0)undec-7-ene in DMF, and the protected 
amino acid residues were coupled with N,N’-diisopropylcarbodiimide/1-
hydroxybenzotriazol. The side chain protecting groups were the following: aspartate, 
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glutamate: tert-butyl ether; threonine, serine, tyrosine: tert-butyl ether; arginine: 
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf); histidine, asparagine, 
glutamine: triphenylmethyl; cysteine: acetamidomethyl. The peptides were acetylated at 
the N terminus and the protecting groups (with the exception of acetamidomethyl) were 
removed by a solution of trifluoroacetic acid–water–phenol–thioanisole–1,2 
ethanedithiol 90:5:7,5:5:2,5 (V/V/m/V/V%), while the unprotected peptides remained 
covalently attached to the pins. The only remainder protecting group, acetamidomethyl 
on cysteine was masking the thiol-group of cysteine, which forms a disulfide bond in 
the folded protein. A negative control peptide (heat shock protein 60 (HSP60_480-489: 
480AKNAGVEGSL489) was synthesized for standardized comparison of antibody 
binding. For verification of peptide synthesis three peptides were subjected to amino 
acid analysis, and their precise amino acid composition was verified. The amino acid 
sequence of each synthetic peptide, as well as further details of the peptide synthesis are 
listed in Table 2 A-B. 
Table 2A. Amino acid sequence of the synthetized peptides of Factor H domain 19 
Amino acid sequence of the synthesized peptides on Factor H short consensus repeat 
domain 19. Numbers indicate the position of the initial and last amino acid of each 
synthesized peptide on Factor H, capitals refer to the single letter amino acid codes. 







Table 2B. Amino acid sequence of the synthetized peptides of Factor H domain 20 
and Factor H-related protein 1 
Amino acid sequence of the synthesized peptides on Factor H short consensus repeat 
domain 20 and part of its homolog region on Factor H-related protein 1. Numbers 
indicate the position of the initial and last amino acid of each synthesized peptide on the 
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respective protein, capitals refer to the single letter amino acid codes. The two amino 
acid difference (serine leucine (S L); valine alanine (V A) between FH and 
FHR1 is highlighted in bold. 














4.6. Antibody binding to the immobilized synthetic peptides of Factor H and 
Factor H-related protein 1 
Serum antibody binding to the overlapping synthetic peptides was determined by a 
modified ELISA, as previously described (Fust et al. 2012). In the current experiments, 
after blocking of the non-specific binding sites with 0.5% gelatin in PBS, pins were 
incubated with 150 L of 1:1000 diluted sera in 0.5% gelatin and 0.05% Tween 20 in 
PBS for 1h at room temperature. Binding of anti-FH antibodies to the immobilized 
peptides was determined using a rabbit anti-human IgG peroxidase-labeled antibody 
(Dako, Agilent Technologies, Santa Clara, CA, United States) in a dilution of 1:5000 
and the TMB detection system with OD read at 450 nm (reference at 620 nm). Pins 
were used repeatedly after thorough washing by sonication in disruption buffer (1% 
sodium dodecyl sulfate and 0.1% 2-mercaptoethanol in PBS). As a negative control 
peptide, the HSP60 fragment from amino acids 480–489 was applied, based on our 
earlier observations, where this peptide showed the lowest binding with human sera 
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(Fust et al. 2012). Data were normalized by the following formula: ODsample/ODmin, 
where ODsample equaled the mean of duplicate OD values of the test samples and ODmin 
the mean binding to the negative control HSP60 peptide. This ratio represents the fold 
change of antibody binding over the background to each peptide. Epitope specific 
autoantibody binding in the acute phase and in remission serum samples are both 
presented according to the above formula. 
4.7. Synthesis and antibody binding of recombinant Factor H 19-20 mutants 
Determination of serum antibody binding to the recombinant FH domains 19–20 
displaying various single amino acid changes was performed with an ELISA-based 
method by Dr. Mihály Józsi and his colleagues at Eötvös Loránd University Budapest, 
as previously described (Bhattacharjee et al. 2015, Nozal et al. 2016). Cloning, 
expression, and purification of FH 19–20 wild type and mutant protein fragments was 
performed according to well-established, published protocols of mutagenesis, 
expression and purification (Jokiranta et al. 2006, Lehtinen et al. 2009, Bhattacharjee et 
al. 2010) using the QuikChange® Multi Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA) and the Pichia-expression system followed by heparin affinity 
chromatography (HiTrap Heparin, Amersham Bioscience). Antibody binding to each 
protein fragment was determined by a microtiter plate assay, where Nunc MaxiSorp 
plates (Thermo Fisher Scientific, Waltham, MA USA) were coated by the protein 
fragments in a concentration of 5 g/mL and patients’ sera was applied according to the 
antibody titer (1:50–1:200). Antibody binding was visualized by the application of 
peroxidase-conjugated anti-human IgG and the TMB detection system. For standardized 
comparison of data, the relative binding to the FH mutant peptides compared to wild 
type FH 19-20 is expressed in percentage, where binding to the wild type peptide is 
100%. 
4.8. Visualization of the linear epitopes and point mutations on the folded Factor H 
structure 
We analyzed the localization of the discovered epitopes on the crystal structure of FH 
domains 19–20 [DOI:10.2210/pdb2g7i/pdb (Jokiranta et al. 2006)] using the SWISS-
PDB Viewer software [(Guex et al. 1997), http://www.expasy.org/spdbv/]. 
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4.9. Statistical analysis 
Data analysis in all our investigations was performed using the GraphPad Prism version 
6.00 for Windows (GraphPad Software, La Jolla, CA, USA, www.graphpad.com). 
Since continuous variables of the above studies failed the Shapiro-Wilk’s normality test, 
non-parametric tests were carried out for group comparisons with two-tailed p values 
calculated, and the significance level set at 0.05. For descriptive purposes, continuous 
variables are displayed as median with interquartile range, while categorical variables 
are indicated with numbers (expressed in percentage). The respective statistical method, 
applied for comparison of datasets is indicated in each figure legend. In addition to the 
correlation analysis, multivariate statistics was carried out for the evaluation of the 
association of pentraxin levels with laboratory markers and clinical status of acute 
phase-TMA patients. Multiple linear regression analysis (on log-transformed variables) 
was used to explore the relationship between covariates of PTX3 and CRP levels, 
whereas logistic regression analysis with one-by-one adjustment for covariates was used 




5.1. Analysis of the association between systemic pentraxin levels and laboratory 
signs of disease activity in thrombotic microangiopathies 
5.1.1. Characteristics of patients with acute phase thrombotic microangiopathy 
selected for the determination of the systemic pentraxin levels 
The pentraxin superfamily consist of the long pentraxin PTX3 and the short pentraxins 
CRP and serum amyloid P, all of which are pattern recognition molecules that share a 
conserved pentraxin domain on their C-terminal ends (Daigo et al. 2016). Both PTX3 
and CRP have been reported to interact with activators and regulators of the 
complement system in vitro (Inforzato et al. 2013, Daigo et al. 2016), however their role 
in pathological complement activation in vivo remains to date unexplained. To explore 
the association of circulatory pentraxin levels with complement consumption in TMA, a 
disease often accompanied by overactivation of the complement cascade, we collected 
blood samples from 171 TMA patients in the acute disease flare and measured the 
systemic CRP and PTX3 levels together with complement activity, factor levels and 
complement activation products. We analyzed our findings in regard to the clinical 
outcome and basic laboratory characteristics of the patients and selected 69 age- and 
sex-matched healthy individuals for comparison, none of whom showed clinical or 
laboratory signs of TMA or an acute inflammatory reaction that could have modified 
the pentraxin levels. Examined clinical and laboratory characteristics of the patients and 
the controls are summarized in Table 3. All enrolled TMA patients presented with 
hemolysis and thrombocytopenia (<150 G/L) at the acute disease flare regardless of 
disease etiology, with the lowest median platelet count (i.e. 16 G/L) in the TTP 
subgroup. ADAMTS13 activity was decreased or deficient in 79% of the patients, and 
by definition it was deficient (i.e. activity below 10%) in all of the TTP patients. Organ 
involvement was present in the form of kidney damage by most of the TMA patients, 
although some of the TTP patients presented with neurological symptoms as a sign of 
central nervous system involvement with no laboratory signs of impaired kidney 
function. Classical laboratory parameters indicative of ongoing TMA in each of the 
study groups are summarized in Table 4. Our TMA patient cohort included patients 
with the following etiologies: STEC-HUS (N=34), aHUS (N=44), secondary TMA 
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(N=63) and TTP (N=30) (Figure 3), with over 90% of the admitted patients presenting 
at the first acute episode of the disease. Blood samples were collected from all subjects 
enrolled prior to the start of plasma exchange or complement inhibitory therapy, 
although 16 patients received FFP before the time of sampling. However, until the time 
point of blood sample collection administration of FFP did not results in an 
improvement of the clinical status or the classical laboratory signs of TMA in any of the 
enlisted patients. 
Table 3. Characteristics of TMA patients and healthy controls 
Group characteristics and laboratory data of the enrolled patients and healthy controls. 
Categorical variables are expressed in percent and continuous variables are shown as 
medians and with interquartile range, whereas results of the statistical comparison are 
indicated with the respective p value of the Mann-Whitney test. (ADAMTS13= a 
disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, 
CRP= C-reactive protein, FH= Factor H, NA= not applicable, PTX3= pentraxin-3, 
sC5b-9= soluble C5b-9, TMA= thrombotic microangiopathy). 
 
Characteristics analyzed TMA Healthy controls 
Result of statistical 
comparison 
Number of individuals enrolled 171 69 NA 
Age 35.2 (7.7-56.9) 33.0 (18.7-41.0) P=0.608 
Sex (male/female in %) 43/57 48/52 NA 
First acute episode (%) 93.6 NA NA 
31-day mortality (%) 11.7 0 NA 
Complement C3 < 0.9 g/L (%) 49.7 0 NA 
Complement FH < 250 mg/L (%) 25.7 0 NA 
Laboratory parameters indicative of ongoing TMA  
Red blood cell count (109/L) 2.9 (2.6-3.4) 4.9 (4.6-5.2) p<0.001 
Hemoglobin (g/L) 85 (75-97) 141 (134-152) p<0.001 
Platelet count (109/L) 46 (22-75) 262 (235-309) p<0.001 
Lactate dehydrogenase (U/L) 1819 (893-3051) Not done NA 
Creatinine ( mol/L) 188 (86-320) 71 (64-78) p<0.001 
Carbamide (mmol/L) 16.9 (10.9-25.9) 4.5 (3.8-5.6) p<0.001 
Pentraxin levels and white blood cell profile  
PTX3 level ( g/L) 5.19 (2.08-13.17) 1.08 (0.75-1.66) p<0.001 
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CRP level (mg/L) 16.9 (4.3-72.0) 1.4 (0.8-2.0) p<0.001 
White blood cell count (G/L) 10.4 (7.1-15.3) 6.5 (5.4-7.9) p<0.001 
Absolute neutrophil count (G/L) 7.1 (4.8-12.4) 4.0 (3.0-4.7) p<0.001 
Absolute lymphocyte count (G/L) 1.4 (0.8-2.6) 2.0 (1.8-2.4) p<0.001 
Complement parameters  
ADAMTS13 activity (%) 
(Reference range: 67-147%) 38 (17-54) Not done NA 
Classical pathway activity 
(CH50/ml) 57 (45-71) 70 (62-77) p<0.001 
Alternative pathway activity (%) 86 (56-101) 101 (78-117) p<0.001 
C3 level (g/L) 0.90 (0.68-1.15) 1.26 (1.18-1.47) p<0.001 
C4 level (g/L) 0.23 (0.14-0.32) 0.34 (0.27-0.40) p<0.001 
Factor H level (mg/L) 390 (245-513) 560 (462-692) p<0.001 
Factor I level (%) 98 (81-123) 102 (92-108) p=0.192 
Factor B level (%) 98 (73-116) 101 (91-113) p=0.791 
C1q level (mg/L) 87 (56-112) 100 (80-124) p=0.020 
sC5b-9 level (ng/mL) (Reference 
range: 110-252 ng/mL) 352 (265-517) Not done NA 
C3a level (ng/mL) (Reference 
range: 70-270 ng/mL) 171 (120-259) Not done NA 
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Table 4. Characteristic laboratory parameters of patients in the distinct TMA 
subgroups 
Laboratory parameters indicative of disease activity are shown in each TMA group. 
Data are expressed as median with interquartile range. Please note that blood count and 
chemistry data were not accessible by all the enrolled patients, therefore the analysis 
might include less than the total number of patients (N=171) in this study. (BUN= 
carbamide, Crea= creatinine, Hb= hemoglobin, aHUS= atypical hemolytic uremic 
syndrome, LDH= lactate dehydrogenase, PLT= platelet count, RBC= red blood cell 
count, STEC-HUS= Shiga-like toxin associated HUS, TMA=thrombotic 
microangiopathy, TTP= thrombotic thrombocytopenic purpura, WBC= White blood cell 
count, ANC= Absolute neutrophil count) 
 
Laboratory 
parameters aHUS N STEC-HUS N Secondary TMA N TTP  N 
RBC (T/L) 2.8 (2.5-3.3) 17 3.3 (2.8-3.7) 31 2.9 (2.6-3.3) 49 2.7 (2.1-3.2) 24 
Hb (g/L) 80 (67-95) 30 87 (76-101) 33 88 (79-95) 53 80 (67-99) 29 
PLT (G/L) 53 (29-86) 32 51 (33-88) 33 50 (34-76) 54 16 (11-27) 29 
LDH (U/L) 2777 (1806-4027) 24 
3280 (2374-














40.1) 32 17.9 (11.7-28.0) 46 6.5 (5.0-9.0) 21 
 
5.1.2. Pentraxin levels in acute phase thrombotic microangiopathy and their 
relation to the laboratory markers of disease and clinical characteristics of patients 
The circulatory PTX3 and CRP levels were significantly elevated in acute phase-TMA 
compared to healthy controls. Elevated PTX3 and CRP levels could be detected in all 
etiological forms of TMA, although PTX3 elevation was exceptional in TTP, despite 
the elevated CRP level in 53% of the TTP patients (Figure 5 A-D). With further 
subdivision of the study groups, we found that the elevation of both pentraxins was 
independent of the molecular background in aHUS or the underlying condition in 
secondary TMA. The calculated cutoff of CRP levels (5.01 mg/L) was equivalent to the 
upper limit of normal range (5 mg/L) used in our laboratory in frames of diagnostics, 
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whereas the cutoff of PTX3 levels was determined based on the levels measured in the 
healthy control group and set as 3.40 g/L. 
PTX3 levels were associated with markers of disease activity and organ damage. We 
observed a significant positive correlation between lactate dehydrogenase (LDH) and 
PTX3 levels, and a weaker yet significant correlation of the platelet count as well as 
laboratory sings of kidney damage to PTX3. By contrast, association between CRP and 
disease activity was not present, except a significant positive correlation to creatinine 
levels. Furthermore, systemic PTX3 and CRP levels showed a strong positive 
correlation to each other and to markers of systemic inflammation such as the white 
blood cell (WBC) and absolute neutrophil counts (ANC) of the patients (Figure 6 A-D). 
Low neutrophil counts may indicate both the disturbance of production with a 
subsequently low PTX3 level, or neutrophil activation and consumption, with a 
consequently high PTX3 level. To generate homogeneous patient groups during the 
assessment of pentraxin production in frames of the TMA-associated inflammatory 
response, we excluded patients with a WBC or ANC below the lower limit of the 
laboratory normal range (WBC < 4G/L, N=10; ANC < 1.8G/L, N=5) from the latter 
analysis. Since platelet count is a reliable marker of disease activity in TMA, we 
grouped the patients according to platelet counts at the time of admission. However, 
despite the positive correlation, we found that irrespective of the classification, PTX3 
and CRP levels of all subgroups remained significantly elevated compared to healthy 
controls (Figure 7 A-B). In order to adjust for confounding variables, the laboratory 
parameters presented in Table 4 were also entered into two multiple regression models 
to explore the relationship between them and the determined pentraxin levels. LDH 
(standardized regression coefficient beta=0.299) turned out to be a significant predictor 
of PTX3 in the multivariable model, whereas platelet and kidney function measures did 
not. For CRP, significant predictors were hemoglobin (beta=0.183), platelet number 




























Figure 5. Systemic PTX3 and CRP levels in TMA patients and healthy controls 
PTX3 and CRP levels of acute phase-TMA patients compared to those of healthy 
individuals are displayed on panels A-B, whereas pentraxin levels of TMA patients 
subdivided based on disease etiology are shown on panels C-D. Data points are 
expressed as mean of technical duplicates, the horizontal line indicates the median of 
each group and an intermittent line indicates the calculated cutoff of each pentraxin, 
respectively. Statistical analysis was performed with the Kruskal-Wallis test corrected 
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for multiple comparisons using the Dunn’s post hoc test. Statistical significance is 
indicated by asterisks (****p<0.0001). (aHUS= atypical hemolytic uremic syndrome, 
CRP= C-reactive protein, PTX3= pentraxin-3, STEC-HUS= Shiga-like toxin associated 






















Figure 6. Correlation of the systemic pentraxin levels to inflammatory parameters 
Correlation of the PTX3 (green circles) and the CRP (grey circles) levels to the WBC 
(panels A-B) and absolute neutrophil counts (panels C-D) of the patients. Laboratory 
normal ranges are shown with grey shading. To generate homogeneous patient groups, 
patients with a WBC below 4 G/L (N=10) and those with an absolute neutrophil count 
below 1.8 G/L (N=5) were excluded from this analysis. Statistical analysis was 
performed with the Spearman correlation analysis. Respective r and p values are 
indicated in the upper right corner of each graph. Please note that blood count and 
chemistry data were not available by all the enrolled patients, therefore the correlation 
analyses might include less than the total number of patients included in this study 
(N=171). Patients with an undetectable pentraxin level (N=3) are not shown in the 
graph, however their data were included in the statistical analysis. (CRP=C-reactive 

































Figure 7. Systemic pentraxin levels and platelet count of TMA patients 
PTX3 (A) and CRP (B) levels of acute phase-TMA patients are shown, subdivided 
based on the platelet count determined at the onset of disease. Data are expressed as 
mean of technical duplicates, the horizontal line indicates the median of each group. 
Statistical analysis was performed with the Kruskal-Wallis test corrected for multiple 
comparisons using the Dunn’s post hoc test. Statistical significance is indicated by 





5.1.3. Association of the systemic pentraxin levels with the acute phase mortality 
In-hospital mortality was followed-up during the first month of the acute disease flare 
and the association of circulatory pentraxin levels to disease mortality was analyzed in 
the secondary TMA subgroup, where mortality exceeded 30% within a 31-day period. 
Conversely, only one patient died in the TTP group, whereas no deaths occurred among 
STEC-HUS or aHUS patients. Elevation of the median PTX3 level was associated with 
a higher acute phase mortality in the secondary TMA group, whereas the median CRP 
levels did not differ significantly in secondary TMA patients who survived the first 
month of the TMA episode compared to those who did not (Figure 8 A-B). Since our 
study augments an earlier publication that focused exclusively on the investigation of 
secondary TMA patients (Farkas et al. 2017), with considerable overlap of the patient 
population, we also performed our analysis following the exclusion of patients included 
in our earlier study. We found that the median PTX3 level remained significantly 
elevated in deceased patients compared to survivors of the acute episode even in the 
narrowed patient population (N=33), while elevation of CRP showed no association to 
disease mortality. 
The optimum PTX3 cut-point was 9 g/mL to differentiate patients who died during 
follow up, from those who survived (odd's ratio 3.08 (95% CI 1.02-9.33)). One-by-one 
adjustment for key activity indicators showed that high PTX3 levels are hemoglobin 
and creatinine independent predictors of mortality, whereas dependent on platelet and 
LDH levels. 
5.1.4. Pentraxin levels in disease remission 
STEC-HUS and secondary TMA are characterized by one acute episode with no disease 
recurrence upon the eradication of the underlying cause. On the other hand, relapses are 
common features of aHUS and TTP with a progressive decline of kidney function and 
neurological deterioration, respectively. To investigate the regression of pentraxin levels 
in disease remission, we obtained follow-up samples from 31 aHUS patients and 19 of 
the TTP patients (Figure 9 A-D). Although the PTX3 level remained significantly 
higher in aHUS remission compared to the healthy control group, the systemic CRP 
levels in remission were similar to those of the healthy controls. In 80% of aHUS both 
PTX3 and CRP levels decreased compared to the paired acute phase samples, 
DOI:10.14753/SE.2020.2318
59 
nonetheless the extent of decline did not reach statistical significance in patients with no 
clarified molecular background of the disease. The initially low PTX3 levels of TTP 
patients showed no remarkable difference in remission, and the CRP levels also 

















Figure 8. Association of the systemic pentraxin levels to disease mortality 
Systemic pentraxin levels of the secondary TMA patients are shown at the acute 
presentation of the disease, grouped based on the 31-day survival of patients (deceased 
patients indicated with black triangles, those who survived with white triangles). Data 
are shown as mean of technical duplicates, the horizontal line shows the median of each 
group, whit an intermittent line indicating the calculated cutoff of each pentraxin. 
Statistical analysis was performed with the Mann-Whitney test. Statistical significance 
is indicated by asterisks (**p<0.01). (CRP= C-reactive protein, PTX3= pentraxin-3, 






























Figure 9. Pentraxin levels in the acute phase and remission of aHUS and TTP 
Measured pentraxin levels in the acute phase (black squares) and in remission (empty 
squares) are shown in aHUS (A-B) and TTP (C-D) patients. (A-B) The aHUS patients 
are displayed grouped by the confirmed molecular background of the disease: 22 cases 






antibodies and the rest (N=11) did not carry any likely pathogenic mutations in the 
complement genes (CFH, CFHR5, CFI, CD46, C3, CFB), THBD or DGKE. Data points 
represent mean of technical duplicates with a continuous line connecting each paired 
sample, and the group medians indicated by a horizontal line. Statistical analysis was 
performed with the Wilcoxon matched-pairs signed rank test, statistical significance is 
indicated by asterisks (**p<0.01; ***p<0.001). (aHUS=atypical hemolytic uremic 




5.2. Investigation of the relation of complement overactivation and systemic 
pentraxin levels in distinct forms of thrombotic microangiopathies 
5.2.1. Laboratory signs of complement consumption in acute phase thrombotic 
microangiopathy and their association to the systemic pentraxin levels 
Complement consumption has been associated to all etiological forms of TMA. Nearly 
50% of our patients also presented with decreased C3 levels indicative of complement 
overactivation, while only 8% of the patients (14/171) showed no signs of complement 
alteration (with C3, C4, FH, FI, FB levels, CP and AP activities together with the 
complement activation product levels within the laboratory normal range). Furthermore, 
we had a notable number of patients with low FH level, originating from all disease 
subgroups, indicative of complement dysregulation in all investigated forms of TMA. 
To assess whether elevated pentraxin levels were associated with complement 
consumption in the acute disease flare, we grouped the patients upon PTX3 and CRP 
levels and observed a strong linkage between the gradual increase in PTX3 and sings of 
complement AP and CP consumption (Figure 10 A-D). Complement CP and AP 
activities were significantly lower in patients with PTX3 above 20 g/L compared to 
those with PTX3 below 5 g/L. Moreover, patients with a PTX3 level exceeding 20 
g/L had a median AP and CP activity below the normal range indicating explicit 
complement consumption. As a result of complement overactivation and factor 
consumption, both C3 and C4 levels were significantly lower in patients with PTX3 
above 20 g/L compared to those below 5 g/L (Figure 11 A-D). However, the gradual 
increase of PTX3 was not accompanied by a decrease in the FH and FB levels and the 
level of the complement activation product sC5b-9 was elevated in all groups regardless 
of the systemic PTX3 level (Figure 12 A-F). By contrast, CRP levels showed no 
association to any of the measured complement activity parameters (Figures 9-11). 
Since a considerable number of patients presented with a CRP level exceeding 20mg/L, 
we analyzed the association between CRP levels and laboratory signs of complement 
consumption in four additional patient subgroups (20mg/L < CRP < 40mg/L; 40mg/L < 
CRP < 60mg/L; 60mg/L < CRP < 80mg/L; 80mg/L < CRP), yet we found no 
association between CRP elevation and laboratory markers of pathological complement 























Figure 10. Association of the systemic PTX3 and CRP levels to the activity of the 
alternative and classical pathways 
TMA patients are subdivided based on the measured systemic PTX3 ( g/L) or CRP 
(mg/L) levels indicated on the x axis, with their AP and CP activities shown on the y 
axis, respectively. The color of each data point indicates the specific form of TMA 
corresponding to Figure 3 (brown= aHUS, red= STEC-HUS, black= secondary TMA, 
grey= TTP). Data are expressed as mean of technical duplicates, the horizontal lines 
indicate the median of each group, whereas the laboratory normal range is shown with 
grey shading. Statistical analysis was performed with the Kruskal-Wallis test corrected 





indicated by asterisks (****p<0.0001). (aHUS= atypical hemolytic uremic syndrome, 
CRP= C-reactive protein, PTX3= pentraxin-3, STEC-HUS= Shiga-like toxin associated 
























Figure 11. Association of the systemic PTX3 and CRP levels to the complement 
factor levels C3 and C4. 
TMA patients are subdivided based on the measured systemic PTX3 ( g/L) or CRP 
(mg/L) levels indicated on the x axis, with their C3 and C4 levels shown on the y axis, 
respectively. The color of each data point indicates the specific form of TMA 
corresponding to Figure 3 (brown= aHUS, red= STEC-HUS, black= secondary TMA, 
grey= TTP). Data are expressed as mean of technical duplicates, the horizontal lines 
indicate the median of each group, whereas the laboratory normal range is shown with 
grey shading. Statistical analysis was performed with the Kruskal-Wallis test corrected 





indicated by asterisks (****p<0.0001). (aHUS= atypical hemolytic uremic syndrome, 
CRP= C-reactive protein, PTX3= pentraxin-3, STEC-HUS= Shiga-like toxin associated 































Figure 12. Complement regulator Factor H, Factor B and the complement 
activation products according to the pentraxin levels in TMA 
Association of the systemic PTX3 and CRP levels to the complement regulators Factor 
H, Factor B and the complement activation product sC5b-9 levels. TMA patients are 
subdivided based on the measured systemic PTX3 ( g/L) or CRP (mg/L) levels 












form of TMA corresponding to Figure 3 (brown= aHUS, red= STEC-HUS, black= 
secondary TMA, grey= TTP). Data are expressed as mean of technical duplicates, the 
horizontal lines indicate the median of each group and the laboratory normal range is 
shown with grey shading. Statistical analysis was performed with the Kruskal-Wallis 
test corrected for multiple comparisons using the Dunn’s post hoc test. (aHUS = 
atypical hemolytic uremic syndrome, CRP= C-reactive protein, PTX3= pentraxin-3, 
STEC-HUS= Shiga-like toxin associated HUS, TMA= thrombotic microangiopathy, 
TTP= thrombotic thrombocytopenic purpura) 
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5.2.2. Impact of excess pentraxin-3 on alternative pathway activity in vitro 
Since in vivo complement consumption was accompanied by a gradual increase in the 
systemic PTX3 level in our acute phase-TMA patients, to explore the functional 
relevance of this phenomenon, we tested whether PTX3 attenuates or stimulates the AP 
activity on the cellular surface in vitro. In a modified hemolytic assay allowing for 
activation of solely the AP, we built up the AP C3-convertase on sheep erythrocytes and 
determined the hemolytic activity of NHS with the addition of recombinant human 
PTX3 or buffer control, respectively (Figure 13A). We found that addition of PTX3 
dose-dependently decreased the AP hemolytic activity on sheep red blood cells. 
Conversely, addition of PTX3 to NHS did not influence the AP activity on the surface 
of ELISA plates and thus resulted in no remarkable change in C9 deposition through 













Figure 13. Effect of PTX3 on alternative pathway activity in vitro 
The effect of recombinant human PTX3 on AP hemolytic activity (A) and 
lipopolysaccharide induced complement C9 deposition (B) is shown in the respective 
figure panels. Data are expressed in percent, compared to buffer control added to pooled 
serum of healthy individuals (100%). Data represent mean of three times repeated 
experiments with technical duplicates, error bars indicate the standard error of mean. 
Statistical analysis was performed with the Kruskal-Wallis test corrected for multiple 
comparisons using the Dunn’s post hoc test. Statistical significance is indicated by 





5.3. Epitope analysis of anti-Factor H antibodies in atypical hemolytic uremic 
syndrome 
5.3.1. Clinical and laboratory characteristics of patients with autoimmune atypical 
hemolytic uremic syndrome 
Sera of children with the diagnosis of autoimmune aHUS were obtained for the epitope 
analysis of FH antibodies. For accurate confinement of the antibody binding epitopes on 
FH, only sera of treatment-naïve patients were applied in the epitope mapping 
experiments in the acute phase of aHUS. The enrolled patients’ anti-FH antibody titers 
in the acute disease flare and remission, as well as the results of MLPA with 
characteristic CFHR1 deficiency are shown in Table 5. The median age of the children 
at the time of diagnosis was 9 years, therefore sera of age-matched control individuals 
(N=10) were applied in the epitope analysis experiments. Serum samples of the eight 
aHUS patients were taken before the initiation of plasmapheresis during the first acute 
episode of the disease, however two of the study subjects received FFP prior to 
sampling. We obtained remission phase sera samples from seven of the patients, who 
were followed-up on a monthly basis after the termination of aHUS-specific therapy. 
This included plasmapheresis, immunosuppression with corticosteroids or 
cyclophosphamide, and rituximab, respectively. The remission phase samples were 
collected after a minimum follow-up period of 6 months in clinical remission, during 
which the patients received no immunomodulation or any forms of plasma therapy (FFP 
or PEX). By definition, the diagnosis of autoimmune aHUS was established based on 
the clinical signs of acute kidney failure and laboratory markers of hemolysis and 
thrombocytopenia with an anti-FH antibody level exceeding the cutoff titer of 110 
AU/mL. Even though the anti-FH antibody level of all patients was higher than the 
internationally established upper-normal limit, there was a notable difference in the 
initial titers of the patients ranging from 209-10067 AU/mL. Furthermore, albeit the 
follow-up periods elapsed devoid of relapse in all of the aHUS patients, the level of free 
anti-FH IgG remained low-titer positive in three out of seven cases (Table 5). 
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Table 5. Patients enrolled in the epitope analysis of anti-Factor H antibodies 
Patients with the diagnosis of aHUS enrolled in this study who had a positive ELISA 
result for anti-FH antibodies (>110 AU/ml) at the time of acute phase presentation. 
Major clinical characteristics and results of the MLPA are displayed by each enrolled 
subject. (aHUS = atypical hemolytic uremic syndrome, anti-FH antibodies = anti-Factor 
H antibodies, ELISA = enzyme-linked immunosorbent assay, MLPA = multiplex 











in the acute 
phase of aHUS 
(AU/ml) 
Anti-FH antibody 
level in remission 
of aHUS (AU/ml) 
MLPA results for 
CFHR1 and CFHR3 
P1 6.5 male 10067 136 Homozygous deletion of CFHR1 and CFHR3 
P2 8.5 male 2190 125 Homozygous deletion of CFHR1 and CFHR3 
P3 10.5 female 1306 93 Homozygous deletion of CFHR1 and CFHR3 
P4 8 female 2221 99 
Homozygous deletion of 
CFHR1 and heterozygous 
deletion of CFHR3 
P5 8 male 2725 213 Heterozygous deletion of CFHR1 and CFHR3 
P6 8 male 209 55 Homozygous deletion of CFHR1 and CFHR3 
P7 11 male 329 89 Homozygous deletion of CFHR1 and CFHR3 
P8 11 female 9152 no sample available 
Homozygous deletion of 
CFHR1 and CFHR3 
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5.3.2. Localization of the linear autoantibody epitopes on Factor H in the acute 
phase and remission of atypical hemolytic uremic syndrome 
Autoantibody binding to the synthetic peptides was investigated by ELISA. Reactivity 
of serum anti-FH antibodies to the synthetic peptides of ten control children and eight 
aHUS patients is shown in Figure 14 A-B. Peptides with a significantly increased 
relative autoantibody binding in the acute disease flare (patients versus control, Mann-
Whitney test) included amino acids 1157-1171 on FH domain 19 (Figure 14A), and 
amino acids 1177-1191 and 1207-1226 on FH domain 20 (Figure 14B). The highest 
average binding was observed to peptides covering the amino acid residues 1212-1226. 
Albeit average autoantibody binding to the linear peptides is presented in the graphs, it 
is noteworthy that all three of the linear epitopes displayed increased autoantibody 
binding in the acute phase sera of every child. In disease remission, the epitope 
recognition pattern of the autoantibodies remained similar compared to what we had 
observed at the acute disease onset, although with weaker signals (Figure 15 A-B). The 
decline of antibody binding reached statistical significance by one of the epitopes 
(peptide 1177-1191) although in case of all epitopes a decrease of at least 25% was 
measured at the level of group mean. 
5.3.3. Comparison of Factor H autoantibody binding to linear epitopes on Factor H 
and Factor H-related protein 1 
The C-terminal domains of FH and FHR1 share a 99% homology and differ only in two 
amino acids (Table 2). Since seven of our patients carried a homozygous, and one a 
heterozygous deletion of CFHR1 (Table 5), we also synthesized overlapping peptides of 
the region containing the two residues which are different in FH and FHR1 (Table 2). 
We identified significantly increased autoantibody binding to peptide 276-290 of FHR1 
compared to controls in the acute phase of aHUS (Figure 14B), which covered the exact 
same location as the previously identified autoantibody epitope on FH (peptide 1177-
1191). Even though in remission antibody binding decreased significantly to the 
homologous epitopes of FH and FHR1 (Figure 15B), the decline only reached statistical 
significance by the FH peptide. The extent of autoantibody binding however, was 
comparable to each of the homologous peptides, suggesting that the serine-leucine 

















Figure 14A. Detection of linear antibody binding epitopes in the acute phase of 
disease 
Relative binding of serum anti-FH antibodies to the synthetic FH peptides of SCR 
domain 19 in control patients and in the acute phase of aHUS. The sera of ten control 
children (black bars) and eight children in the acute phase of HUS (white bars) were 
analyzed, data are displayed as mean relative autoantibody binding per group with the 
standard error of the mean. Relative autoantibody binding is expressed as the ratio of 
ODsample/ODmin, where ODsample is the mean of duplicate OD values of the test samples 
and ODmin is the mean binding to the negative control HSP60 peptide. Numbering on 
the x axis shows the initial and final amino acid of each tested peptide. Difference in 
autoantibody binding to the peptides was determined with Mann-Whitney test. 
Statistical significance is indicated by asterisks (**p<0.01). (aHUS = atypical hemolytic 
uremic syndrome, FH = Factor H, anti-FH antibodies = anti-Factor H antibodies, HSP60 




























Figure 14B. Detection of linear antibody binding epitopes in the acute phase of 
disease 
Relative binding of serum anti-FH antibodies to the synthetic peptides of FH SCR 
domain 20 (upper panel) and the fragment of FHR1 SCR domain 5 (lower panel) 
homolog to that of FH amino acids 1177-1211 in control patients and in the acute phase 
of aHUS. The sera of ten control children (black bars) and eight children in the acute 
phase of HUS (white bars) were analyzed, data are displayed as mean relative 
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autoantibody binding per group with the standard error of the mean. Relative 
autoantibody binding is expressed as the ratio of ODsample/ODmin, where ODsample is the 
mean of duplicate OD values of the test samples and ODmin is the mean binding to the 
negative control HSP60 peptide. Numbering on the x axis represents the initial and final 
amino acid of each tested peptide. Difference in autoantibody binding to the indicated 
peptides was determined with Mann-Whitney test. Statistical significance is indicated 
by asterisks (*p<0.05). (aHUS = atypical hemolytic uremic syndrome, FH = Factor H, 

















Figure 15A. Detection of linear antibody binding epitopes in remission 
Epitope specific relative anti-FH antibody binding to the linear epitopes of FH SCR 
domain 19 in remission (grey bars) versus the acute phase (white bars) of atypical 
hemolytic uremic syndrome (aHUS). Analysis of seven patients is displayed as mean 
relative autoantibody binding per group with the standard error of the mean. Relative 
autoantibody binding is expressed as the ratio of ODsample/ODmin, where ODsample is the 
mean of duplicate OD values of the test samples and ODmin is the mean binding to the 
negative control HSP60 peptide. Numbering on the x axis shows the initial and final 
amino acid of each tested peptide. Statistical analysis for the difference in autoantibody 
binding to the peptides was performed using the Wilcoxon matched-pairs signed rank 
test (aHUS = atypical hemolytic uremic syndrome, FH = Factor H, anti-FH antibodies = 



























Figure 15B. Detection of linear antibody binding epitopes in remission 
Epitope specific relative anti-FH autoantibody binding to the linear epitopes of FH SCR 
domain 20 (upper panel) and the fragment of FHR1 SCR domain 5 (lower panel) 
homolog to that of FH amino acids 1177-1211 in remission (grey bars) versus the acute 
phase (white bars) of atypical hemolytic uremic syndrome (aHUS). Analysis of seven 
patients is shown as mean relative autoantibody binding per group with the standard 
error of the mean. Relative autoantibody binding is expressed as the ratio of 
ODsample/ODmin, where ODsample is the mean of duplicate OD values of the test samples 
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and ODmin is the mean binding to the negative control HSP60 peptide. Numbering on 
the x axis shows the initial and final amino acid of each tested peptide. Statistical 
analysis for the difference in autoantibody binding to the peptides was performed using 
the Wilcoxon matched-pairs signed rank test. Statistical significance is indicated by 
asterisks (*p<0.05). (aHUS = atypical hemolytic uremic syndrome, FH = Factor H, anti-




5.3.4. Fine epitope mapping of recombinant Factor H domains 19-20 expressing 
atypical hemolytic uremic syndrome-associated point mutations by anti-Factor H 
autoantibodies of atypical hemolytic uremic syndrome patients 
Pathogenic mutations associated with aHUS are most frequently located on the C-
terminal SCR domains of FH and their presence results in the loss of host recognition 
and C3b binding by the complement regulator. Since antibody binding to FH also 
arrests these functions of the protein, we applied various recombinant FH19-20 
constructs displaying single amino acid changes associated with aHUS to locate those 
that are involved in antibody binding, and to validate the results of the linear epitope 
mapping on the folded FH domains. For this purpose 14 different constructs were tested 
in ELISA (Figure 16) using serum samples of three patients. On the folded FH domains 
a distinct antibody binding epitope appeared between amino acids 1183-1198, with a 
symmetric gradual decline in antibody binding towards amino acid 1188. We observed 
the highest decrease in anti-FH binding to the FH 19-20 construct with a point mutation 
at amino acid position 1188. Additional positions, where an amino-acid switch 
significantly decreased the anti-FH antibody binding were detected on domain 19 
(amino acids 1139 and 1157) and the C-terminal end of domain 20 (amino acids 1210 
















Figure 16. Epitope mapping of single amino acid-substituted FH constructs by 
anti-FH autoantibodies of aHUS patients 
Anti-FH antibody binding to recombinant human FH domains 19-20, substituted with 
single amino acid-mutations (grey bars) is shown compared to the wild type protein 
domains (striped bar). The single letter amino acid codes of the substitutions are 
indicated on the x axis with capital letters and numbers marking their location. Binding 
is expressed on the y axis in percent relative to that of the wild type (100%). We tested 
the sera of three patients in the acute phase of aHUS, mean and standard error of the 
mean from three independent experiments is displayed on the graphs. Statistical analysis 
was performed with the one-sample Wilcoxon Signed Rank test, statistical significance 
is indicated by asterisks (*p<0.05; **p<0.01;). (aHUS = atypical hemolytic uremic 
syndrome, anti-FH antibody = anti-Factor H antibody, WT FH= wild type Factor H) 
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5.3.5. Position of the linear Factor H epitopes and atypical hemolytic uremic 
syndrome-associated point mutations on the crystal structure of Factor H 
To verify the observations of the distinct approaches of epitope mapping we visualized 
the location of the linear epitopes and single amino acid-substitutions in the tertiary 
structure of FH obtained from the Protein Data Bank (ID: pdb2g7i) (Figure 17A). We 
also positioned the linear epitopes on the amino acids participating in C3b and sialic 
acid binding (Figure 17B), to explore the potential functional relevance of FH blockade 
by autoantibodies. In the steric conformation, epitope 1157-1171 appears as a linear 
segment in the hinge region between FH domains 19 and 20, while epitopes 1177-1191 
and especially 1207-1226 are in close sterical proximity with the C-terminal end of 
peptide 1157-1171. The data obtained from the linear and fine epitope mapping 
experiments is summarized in Table 6, linked to the role of each amino acid in C3b as 





















Figure 17. Visualization of the linear epitopes and point mutations on Factor H 
Ribbon model of the folded structure of Factor H (FH) short consensus repeat (SCR) 
domains 19-20 obtained from the Protein Data Bank (ID: pdb2g7i). Linear epitopes of 
the anti-Factor H autoantibodies are highlighted with orange (amino acids 1157-1171, 
1177-1191, 1207-1221), arrowheads point towards the C-terminal end of the protein and 
the initial and final amino acid (aa) of each segment is indicated with black numbers. 
(A) The location of the generated amino acid switches is displayed as colorful spheres 
on the backbone of the protein, with white numbers pinpointing their location and colors 
representing their effect on autoantibody binding by FH (red: significantly decreased 
binding when the aa substitutions is present, green: no significant effect on binding). (B) 
Colorful spheres refer to amino acids forming the C3b (Morgan et al. 2011, Strobel et 
al. 2011) (light blue) and sialic acid (Blaum et al. 2015) (dark blue) binding sites of the 
molecule with numbers within the spheres showing the aa location on FH. 
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Table 6. Overlap of the antibody binding epitopes with sites of C3b binding and 
sialic acid recognition on Factor H 
Association of the identified linear epitopes and the atypical hemolytic uremic 
syndrome-associated point mutations on Factor H domains 19-20 to C3b and sialic acid 
binding sites of the protein. The position of the investigated amino acids is shown in the 
first column with the single letter amino acid code of the indicated location. Single 
amino-acid switches that overlapped the identified epitopes are highlighted in orange, 
corresponding to Figure 17, whereas their involvement in C3b or sialic acid binding is 
shown with a plus sign (+). 
Location of 
amino acids C3b binding 
Sialic acid 
binding 
Significant decrease in anti-FH Ab 









D1119 not tested 
Q1139 + yes 
Y1142 + not tested 
W1157 yes 
1157-1171 P1166 + not tested 
I1169 + not tested 
R1182 + yes 
1177-1191 
W1183 yes 
T1184 + yes 
K1186 yes 
K1188 + yes 
L1189 + yes 
Y1190 + not tested 
S1191 + not tested 







V1197 + not tested 
E1198 + yes 









6.1. Elevation of the systemic pentraxin levels in the acute phase of thrombotic 
microangiopathies and their association to complement overactivation and 
consumption 
TMAs are life-threatening conditions with pathological activation of both the 
coagulation and complement cascades that evoke a systemic inflammatory response in 
the acute phase of disease (Noris et al. 2012). Our understanding of the pathophysiology 
and characteristic course of distinct TMA forms has substantially improved in recent 
years with novel genes, pathways and mechanisms described as a result of intensive 
research of this field. The distinct etiological forms of TMA have recently been 
associated with neutrophil cell activation and the release of NETs (Walters et al. 1989, 
Fitzpatrick et al. 1992, Ishikawa et al. 2000, Fuchs et al. 2012, Mikes et al. 2014), as a 
component of which PTX3 may be secreted at the site of tissue damage. During the 
acute phase of the disease, activation of innate immunity also stimulates the production 
of CRP. We chose to investigate the relation of these two pentraxins with laboratory 
markers of disease activity, to provide observational data on the systemic levels of 
pentraxins in the acute phase of TMA. We hypothesized that there is a potential 
association between the complement activation status and the systemic level of 
pentraxins in vivo, based on the reported interaction of pentraxins with members of the 
complement system, and the complement mediated tissue injury present in TMA. 
We report on the significant elevation of the fluid phase PRMs CRP and PTX3 in the 
acute phase of TMA and their association with laboratory markers of disease severity, 
signs of complement consumption and laboratory markers of the ongoing inflammatory 
response. We detected elevated CRP levels in all subgroups of TMA, regardless of the 
underlying etiology. PTX3 levels on the other hand were only elevated in STEC-HUS, 
aHUS and secondary TMA, however not in TTP (Figure 5C). 
Elevation of the CRP levels could be detected in over half of the acute phase-TTP 
patients, which remained so in 20% during disease convalescence. The sole elevation of 
CRP without a concomitant increase in the PTX3 levels may be attributed to a 
considerable IL-6 response in the acute phase of TTP (Westwood et al. 2014) that drives 
CRP production in the liver (Bottazzi et al. 2006) whereas local generation of PTX3 is 
IL-6-independent (Alles et al. 1994, Basile et al. 1997, Luchetti et al. 2000), which 
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could in part explain the lack of PTX3 elevation in TTP. However, neutrophil cell 
activation together with complement dysregulation have been noted in TTP (Reti et al. 
2012, Mikes et al. 2014) and the white blood cell as well as the absolute neutrophil 
counts were similar in all etiological subgroups of TMA, suggesting a similar extent of 
PTX3 production by neutrophils in all subgroups, including TTP. On the other hand, 
absence of elevation in the systemic PTX3 levels in TTP may also be associated with an 
enhanced consumption of the released protein. PTX3 was reported to inhibit 
thrombocyte aggregate formation through the binding of activated platelets under 
pathological conditions (Maugeri et al. 2011). This phenomenon could also be present 
in TTP, where thrombocytopenia is more severe than in the rest of TMA (Maugeri et al. 
2011). Accelerated platelet consumption therefore may result in the depletion of free 
PTX3, thus causing low or undetectable systemic levels of the protein in the sera of TTP 
patients. However, it cannot be excluded that additional factors arising from the distinct 
pathogenesis of TTP (e.g. lack of kidney damage) have also contributed to the observed 
difference, the detailed exploration of which were beyond the scope of our 
investigation. 
In approximately 60% of aHUS genetic alterations in the complement genes or 
antibodies directed against FH are accountable for the evoked dysregulation of the AP 
(Kavanagh et al. 2013). In our aHUS cohort the representation of autoimmune aHUS 
was somewhat higher than the previously reported prevalence (25% versus 10%) 
together with a relatively small proportion of unexplained cases (25% versus 30-40%) 
(Kavanagh et al. 2013). When dividing the patients based on the confirmed molecular 
background of the disease, we found that elevated pentraxin levels were present in all 
aHUS subgroups independent of the molecular etiology. PTX3 and CRP elevation was 
also prominent in STEC-HUS and secondary TMA, regardless of the heterogenic 
etiological background of the patients. 
Acute phase disease mortality was associated with a higher median PTX3 level in our 
secondary TMA patients. This relationship was independent of the subjects’ 
hemoglobin and creatinine levels, but was related to platelet and LDH. We recorded the 
highest acute phase mortality (30.2%) in this TMA subgroup, an observation similar to 
those reported in literature (Farkas et al. 2017, Sun et al. 2018), whereas no deaths 
occurred in the aHUS and STEC-HUS patient groups and only one patient was lost 
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among TTP. In contrast with PTX3, no considerable difference could be detected 
between the median CRP levels of the deceased patients compared to those who 
survived the first month of the acute episode. Albeit CRP is used as an established 
marker of inflammation in the clinical practice, PTX3 has also been reported to predict 
both long and short-term disease outcome in an increasing number of conditions (Lin et 
al. 2013, Sjoberg et al. 2014, Zhou et al. 2016, Krzanowski et al. 2017, Hu et al. 2018, 
Lee et al. 2018), whereas some studies even place PTX3 superior to CRP as a predictor 
of mortality (Lin et al. 2013). 
We discovered a strong association between the systemic PTX3 levels and laboratory 
signs of complement consumption in the acute phase of TMA, but no connection in this 
regard could be detected with CRP. According to previously published observations, 
under definite experimental conditions the net result of the PTX3-complement 
interaction is restrain of terminal pathway activity on non-activator surfaces, which aids 
the homeostatic mechanism of phagocytosis and clearance of cellular debris (Inforzato 
et al. 2013, Daigo et al. 2016). This finding is corroborated by human studies, where 
PTX3 has been shown to correlate with established markers of disease severity in 
cardiovascular and renal diseases (Maekawa et al. 2011, Lech et al. 2013, Speeckaert et 
al. 2013) and molecular characterization of this association suggests that PTX3 is 
involved in the fine tuning of inflammation with an overall host-protective effect 
(Maugeri et al. 2011, Bonacina et al. 2013). However reports on animal models of tissue 
damage are controversial in regard to the contribution of PTX3 to the evoked cellular 
damage and inflammatory response, depending on the applied disease model (Souza et 
al. 2002, Salio et al. 2008, Souza et al. 2009, Lech et al. 2013). Neutrophil cell 
activation and NET formation has been reported in all forms of TMA (Walters et al. 
1989, Fitzpatrick et al. 1992, Ishikawa et al. 2000, Fuchs et al. 2012, Mikes et al. 2014). 
As a component of NETs, excess PTX3 may be released on demand from the assembled 
leukocyte infiltrates (Jaillon et al. 2007, Kunes et al. 2012), albeit its production by 
injured endothelial cells and innate immune cells at the site of tissue injury also 
significantly contributes to the locally increased PTX3 levels (Kunes et al. 2012). As a 
NET component, PTX3 may either aggravate or restrain the overactivation of 
complement. A potential regulatory role of PTX3 on AP activity is suggested by its 
recruitment of complement regulators to the cell surface or the ECM (Deban et al. 2008, 
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Kopp et al. 2012) that may limit the expansion of complement-mediated tissue damage. 
Activated complement proteins on the other hand may stimulate the formation of NETs 
that in turn provide a platform for further activation of both coagulation and 
complement (de Bont et al. 2018). 
We aimed to explore the functional relevance of the described association through the 
measurement of alternative pathway activity in the presence of excess PTX3. We 
explored the in vitro effect of PTX3 on the overall activity of the AP using two 
modified assays routinely used in the determination of the whole complement AP 
activity, where we replaced the patients’ sera with NHS with or without external PTX3. 
First, we built up the C3 convertase on sheep erythrocytes under conditions allowing for 
AP activation only to assess the AP hemolytic activity. Second, we assessed C9 
generation on the surface of ELISA plates via LPS-induced AP activation. The major 
difference between the two methods is the composition of the platform provided for the 
assembly of the consecutive steps in the activation of the AP. In the hemolytic assay the 
surface of red blood cells provides the activation scaffold, whereas in the AP ELISA C9 
deposition occurs on the surface of a plastic well. Based on the gradual decline of the 
hemolytic activity parallel to the increment of PTX3 concentration in pooled human 
serum, we conclude that local release of PTX3 may indeed play an important role in the 
limitation of AP activity. However, this restrain is most probably due to an indirect 
effect (e.g. via recruitment of complement regulators to the cellular surface) rather than 
direct inhibition of the activation pathway, as indicated by the lack of AP decline, when 
the activation was induced on the surface of an ELISA well. Nonetheless, local 
regulation of the AP via excess PTX3 could possibly aid the attenuation of the 
endothelial damage in TMA. 
Although we could not detect an association between the patients’ CRP levels and 
complement consumption, in vitro evidence suggests that through the binding of 
complement regulators and the restrain of excess terminal pathway activity, CRP as 
well as PTX3 are able to regulate the AP and CP of complement (Sjoberg et al. 2006, 
Biro et al. 2007, Inforzato et al. 2013, Thiele et al. 2014, O'Flynn et al. 2016). However, 
since CRP production is induced in the liver in frames of a systemic inflammatory 
response, it may not closely reflect the degree of local endothelial damage and 
subsequent overactivation of complement. 
DOI:10.14753/SE.2020.2318
90 
Our observations may indicate a potential practical use of PTX3 determination as a 
biomarker and determinant of complement consumption in the acute phase of TMA. 
However, since this is the first investigation that provides in vivo data on the association 
of elevated systemic PTX3 and laboratory signs of complement consumption, further 
independent investigations are required to confirm the potential use of the PTX3 
measurement as a biomarker of this disease. Nonetheless, the strength of our data is its 
additional value to so far in vitro investigations that described the PTX3-complement 
interaction, and thus our results provide proof for the in vivo relevance of this 
connection. Furthermore, the observed increment in the production of PTX3 in TMA 
may indicate a role for this molecule in the disease pathogenesis. However, apparent 
limitations of our study are the retrospective enrollment of patients and the rare nature 
of this disease that together may have caused some of our analyses to be underpowered. 
The limited number of study subjects and subsequently low case and event numbers in 
this study precluded multivariate analysis in different etiology based subgroups of 
TMAs, therefore some of our observation may represent overestimation of true effects 
due to the lack of adjustment for important clinical and/or laboratory covariates. These 
factors further substantiate the need for the independent confirmation of our 
observations before firm conclusions can be reached on the contribution of PTX3 to the 
pathogenesis of TMA. Ultimately, our results add to a better understanding of TMA 
disease pathogenesis, and the reported association of elevated PTX3 levels and 
complement consumption hopefully may fuel further in vitro investigations that 
characterize the molecular role of PTX3 in TMA. 
6.2. Epitope analysis of anti-Factor H antibodies 
In frames of the investigation of the FH-autoantibody interaction in aHUS our specific 
aim was to identify the antibody binding epitopes on the C-terminal domains of the 
complement regulator. Here, we tested the binding capacity of serum antibodies to 
synthetic linear peptides and recombinant folded domains of FH and to synthetic 
peptides of FHR1. We identified for the first time three linear, extended autoantibody 
binding epitopes on FH, one of which was also recognized on its homologous region on 
FHR1. The described epitopes were recognized by serum autoantibodies both in the 
acute phase and remission of aHUS, albeit we observed a considerable decline in 
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autoantibody binding in convalescence. We propose that the autoantibody binding site is 
formed by the linear epitopes in the tertiary structure, and overlaps with multiple ligand 
binding epitopes of the complement regulator, thus inducing the dysfunction of FH 
similar to that observed in the presence of aHUS-associated FH mutations (Figure 17). 
Besides, detection of a linear epitope on FHR1 confirms its previously observed cross-
reactivity with FH autoantibodies (Moore et al. 2010, Strobel et al. 2011), which further 
substantiates the role of FHR1 in aHUS pathogenesis. 
We chose two complementary approaches for the localization of the autoantibody 
binding epitopes on FH. Our primary goal was to identify the anti-FH antibody epitopes 
on the amino acid level, however for the modelling of the tertiary protein structure, 
application of recombinant, folded FH domains was inevitable. The obtained results of 
the mutant domain and linear epitope mapping were concurrent on both domains 19 and 
20 of FH. The biggest reduction in target recognition could be observed when mutations 
to amino acids 1183-1198 of FH domain 20 were present (Figure 16). The hence 
emerging binding motif overlapped the location of the linear epitope 1177-1191, while 
on the C-terminal end of domain 20 the identified linear epitope 1207-1226 was 
validated by the reduced domain recognition of R1210A and R1215Q (Figure 17). 
These data are in line with previously published observations (Bhattacharjee et al. 2015, 
Nozal et al. 2016) that tested antibody binding to FH fragments both from aHUS patient 
sera and isolated IgG. Nonetheless, our results supplement literature data with the 
identification of the antibody binding sites on the amino acid level. 
The location of the identified epitopes corresponds to the described impairment of the 
cell-associated regulator functions of FH in aHUS. The mutation Q1139A on SCR 
domain 19 and two of the linear epitopes (1157-1171; 1177-1191) involve amino acids 
reported to participate in the binding of C3b (Kajander et al. 2011, Morgan et al. 2011), 
hence explaining the reduced C3b recognition of FH in the presence of autoantibodies 
(Jozsi et al. 2007). Furthermore, the linear epitope on the C-terminal end of domain 20 
(amino acids 1207-1226) covers the reported heparin and sialic acid binding sites of FH 
(Kajander et al. 2011, Blaum et al. 2015), which suggests a hindered attachment to host 
surface sialic acids and heparin for autoantibody-bound FH. In addition to direct 
binding of surface elements, FH may be recruited to the host membrane by surface-
bound pentraxins, too (Deban et al. 2008). The interaction with fluid phase PRMs 
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involves the middle SCRs 6-7 and the most C-terminal domains of FH (Sanchez-Corral 
et al. 2018). Namely, the reported PTX3 binding site on SCR 20 of FH involves amino 
acids 1180-1186 and 1198-1204 (Kopp et al. 2012), which partially overlaps with the 
identified autoantibody specific epitope 1177-1191. Since complement regulation 
through FH is fulfilled via discrimination between specific surface elements of intact 
host tissues and foreign moieties or damaged self-structures, inhibition of target 
recognition could lead to a severe dysfunction of AP regulation by FH. In the presence 
of autoantibodies, their simultaneous interference with both C3b binding and host-
discrimination provides molecular basis for AP dysregulation on host surfaces, most 
probably via the inhibition of the C3b-sialic acid-FH complex formation (Hyvarinen et 
al. 2016). Moreover, due to impaired binding of surface-attached PRMs, antibodies may 
also interfere with the clearance of apoptotic and damaged cells (Kopp et al. 2012), 
further aggravating the overactivation of complement. 
Similar to the patients’ antibody titers at the presentation of aHUS (Table 5), the extent 
of autoantibody binding to the linear epitopes also showed a matching, however 
considerable difference in the individual samples. It is therefore important to mention 
that all three of the identified linear epitopes showed increased autoantibody binding 
compared to the background reactivity in every patient’s serum. Besides, although the 
level of epitope specific antibodies decreased in disease remission, their binding pattern 
remained the same with autoantibody positivity (>110 AU/ml) in three of our patients, 
but no relapse recorded during the follow-up period. The documented presence of anti-
FH antibodies in remission together with the reported possibility of anti-FH positivity in 
healthy individuals (Sinha et al. 2014) further corroborate the concept that in addition to 
the known predisposing factors of aHUS, an environmental trigger event is necessary to 
evoke the clinical manifestation of disease, not only by the first acute episode but also 
before relapses. 
One of these hypotheses outlines the importance of the homozygous deficiency of 
CFHR1, which is by itself not a prerequisite for antibody production, yet it is a very 
common genetic alteration in aHUS patients with anti-FH positivity (Zipfel et al. 2007, 
Jozsi et al. 2008, Dragon-Durey et al. 2010, Geerdink et al. 2012, Hofer et al. 2013). 
Lack of FHR1 together with an environmental trigger (e.g. infection) was proposed to 
induce the formation of a neoepitope on FH domain 20, similar in structure to its 
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homologous region on FHR1 domain 5, and hence prompt the production of 
autoantibodies targeting this region (Bhattacharjee et al. 2015). Our results are in line 
with this hypothesis in regard to the observed similar pattern and extent of antibody 
binding to the linear epitopes of both FH (1177-1191) and FHR1 (276-290), despite 7 of 
our patients being deficient for CFHR1. Albeit the C-terminal domains of FHR1 have a 
lower avidity towards the anti-FH antibodies than their counterparts on FH 
(Bhattacharjee et al. 2015), the two proteins share a high sequence homology and FHR1 
was reported to cross-react with the anti-FH antibodies as well as to neutralize their 
effect in vitro (Moore et al. 2010, Strobel et al. 2011). These observations further 
conform the observed similarities in the antibody binding epitopes of FH and FHR1 in 
our experiments. However, an important a limitation of our study was the application of 
linear synthetic peptides with an equal accessibility, whereas under physiological 
circumstances some of the identified epitopes may be hidden in the cryptic 
conformation of FH. Furthermore, a considerable proportion of autoimmune aHUS 
patients do not carry a genetic alteration in the CFHR genes (Dragon-Durey et al. 2009, 
Moore et al. 2010, Strobel et al. 2011, Geerdink et al. 2012), while anti-FH antibodies 
may also bind additional domains of FH (Moore et al. 2010, Blanc et al. 2012), which 
together suggest the imperfection of our knowledge on the molecular background of 
disease pathogenesis. 
To visualize the spatial composition of the linear antibody binding epitopes, we 
positioned them on the folded domains of FH together with the generated single-amino 
acid switches and known binding sites of C3b and sialic acid (Figure 17). Based on the 
tertiary structure of FH downloaded from the Protein Data Bank, we conclude that the 
identified epitopes are located close to each other on the folded domains of the 
complement regulator. The middle of fragment 1177-1191 protrudes from the surface of 
the protein with high accessibility of the amino acid residues 1185-1187, which could 
explain the significantly decreased antibody binding when point mutations are present 
in this region. The C-terminal epitope 1207-1226 forms a loop, centering in a turn 
structure of 1219-1222, and the residues of the turn are close to the C-terminal end of 
peptide 1157-1171 (1163-1167), just like the C-terminal residues of the linear epitope 
1177-1191. All in all, the C-terminal residues of 1177-1191 and the turn region of 1207-
1226 sandwich the middle of the 1157-1171 sequence and this configuration of the 
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linear epitopes overlaps the reported ternary complex of FH, sialic acids and the C3b 
thioester-containing domain (Figure 17). Therefore, binding of the autoantibodies to any 
of the linear regions either alters the conformation of the combined binding site or 
interferes with C3b and sialic acid recognition by FH through steric hindrance, a 
hypothesis further substantiated by the clustering of aHUS-associated FH mutations at 
this region (Bhattacharjee et al. 2015). 
Taken together we have shown that the aHUS specific autoantibodies recognize three 
distinct linear epitopes on FH and one on FHR1, which show increased autoantibody 
binding not only in the acute phase of aHUS but also in disease remission. The presence 
of an autoantibody specific epitope on FHR1 underlines its role in aHUS pathogenesis, 
although its exact function in disease pathogenesis remains to be defined in future 
studies. We validated the presence of the autoantibody binding epitopes using 
recombinant FH domains 19-20 that carried aHUS-associated point mutations on the C-
terminal domains of the protein. We found that the linear binding sites on FH are 
located close to each other in the tertiary structure, which may suggest the formation of 
a conformational antibody binding site during in vivo folding. The novelty of our work 
lies in the direct mapping of the autoantibody binding site on FH and FHR1 using 
synthetic peptides of the complement proteins, which in the long term may help us to 
design specific inhibitors of anti-FH antibodies and also adds to the exploration of the in 




In frames of our investigations we explored the role of pentraxins in TMA and the 
molecular background of complement dysregulation in autoimmune aHUS. We studied 
the role of PTX3 and CRP in association with complement consumption in the acute 
phase of TMA. In frames of this we provide a detailed description of acute phase-TMA 
patients’ complement profile linked to changes in the systemic pentraxin levels. We 
report that PTX3 elevation is present in the acute phase of STEC-HUS, aHUS and 
secondary TMA but is exceptional in TTP, whereas an elevation in the systemic CRP 
level was detected regardless of disease etiology during the acute disease flare. We 
observed the highest acute phase mortality in secondary TMA patients, which was 
associated with high PTX3 but not CRP levels. Furthermore, laboratory signs of 
complement activation and consumption were detected in the majority of our patients, 
regardless of the etiological background of TMA. We show for the first time that AP 
and CP consumption are associated with elevated PTX3 in the acute phase of the 
disease, and we confirmed in vitro that PTX3 limits AP activity on the surface of red 
blood cells, with no effect on terminal pathway assembly during LPS-induced AP 
activation on ELISA plates. This is the first study where the association of PTX3 and 
CRP elevation has been investigated in a complement mediated disease in vivo, and thus 
our results provide a missing link between the numerous in vitro observations that 
described the interaction of PTX3 with the complement system under defined 
experimental conditions. Through the epitope analysis of anti-FH antibodies we 
identified three linear, extended autoantibody binding epitopes on FH and one on FHR1. 
These epitopes were recognized by both acute phase and remission phase serum 
autoantibodies of aHUS patients and their close sterical proximity on the folded FH 
domains suggests that they form of joint antibody binding site in the tertiary structure. 
The identified epitopes overlap with the reported clustering of aHUS-associated FH 
mutations, as well as with the FH fractions necessary for ligand binding, which provides 
molecular basis for the reported dysfunction of autoantibody-bound FH, ultimately 
leading to the dysregulation of the complement AP. In conclusion, we aimed for the 
investigation of specific molecular aspects of complement dysregulation in aHUS and 
TMA and our results hopefully add to the better understanding of the complex 




The complement system composes a main branch of the humoral immune response that 
plays an important role in the elimination of pathogens and altered self-structures. 
However, dysfunction or inefficiency of its regulatory mechanisms may lead to 
overactivation of the cascade with substantial host-tissue injury, such as endothelial 
damage in TMA. Since complement overactivation may contribute to the vascular 
damage in all forms of TMA, the detailed characterization of the molecular factors 
interfering with complement regulation is of particular importance in the research of this 
disease. In frames of our investigations we chose to explore the association of CRP and 
PTX3 elevation with complement consumption and disease activity in the acute phase 
of TMAs, and furthermore to analyze the interaction between FH and anti-FH 
autoantibodies to reveal the structural bases of FH inhibition in aHUS. We determined 
the systemic levels of CRP and PTX3 to reveal the potential association of the 
circulatory pentraxin levels with complement consumption and disease activity in the 
acute phase of TMA. In this regard we conclude that the acute phase of all etiological 
forms of TMA might be accompanied by the elevation of CRP, whereas PTX3 elevation 
is present in aHUS, STEC-HUS and secondary TMA but is exceptional in TTP. Both 
PTX3 and CRP correlated to laboratory markers of disease severity, whereas PTX3 
elevation was even associated with the acute phase disease mortality in secondary 
TMA. PTX3 levels showed an association to laboratory signs of complement 
consumption, and inhibited the whole complement AP activity in vitro, which suggests 
a protective role of the locally released PTX3 at the site of endothelial damage in TMA. 
During the investigation of the FH anti-FH interaction we identified three linear 
epitopes on the C-terminal domains of the regulator and one on its related protein, 
FHR1. Based on the location of the identified epitopes on the folded domains of FH, we 
propose that the linear epitopes might jointly form a conformational antibody binding 
site in the tertiary structure that overlaps with reported ligand binding sites of FH. 
Antibody binding to the identified epitopes was detected both in the acute phase and 
remission of aHUS, and we recorded a similar extent of antibody binding to the 
homologous regions on FH and FHR1, confirming the previously reported cross-




A komplement rendszer fontos szerepet játszik a patogén kórokozók és megváltozott 
saját struktúrák szervezetünkb l való eltávolításában. A kaszkád szabályozó 
mechanizmusainak károsodása azonban túlaktivációhoz és saját szöveteink (például 
endotél sejtek) jelent s károsodásához és ezen keresztül komplement-mediálta 
betegségek, többek között trombotikus mikroangiopátiák (TMA) kialakulásához 
vezethet. A közelmúlt intenzív kutatási eredményei jelent sen hozzájárultak a TMA-k 
patogenezisér l szerzett ismereteink b vüléséhez és a betegség kialakulásában szerepet 
játszó molekuláris tényez k megismeréséhez. Mivel a komplement rendszer 
túlaktivációja minden TMA forma kialakulásában szerepet játszhat, a kaszkád 
regulációját károsító molekuláris mechanizmusok azonosítása különös fontossággal bír 
ezen betegségcsoport vizsgálatában. Munkánk során célul t ztük ki a szisztémás C-
reaktív protein (CRP) és pentraxin-3 (PTX3) szint emelkedés összefüggésének 
vizsgálatát a betegségaktivitással és a komplement rendszer túlm ködésének 
laboratóriumi jeleivel különböz  etiológiájú TMA formákban. Ezt követ en a H faktor 
(HF) és az ellene termelt autoantitestek közötti kapcsolatot karakterizáltuk, hogy 
feltérképezzük a HF gátlás molekuláris mechanizmusát atípusos hemolítikus urémiás 
szindrómában (aHUS). A pentraxin szintek TMA akut szakaszában és remissziójában 
való meghatározása során a következ ket állapíthatjuk meg. Az etiológiai háttért l 
függetlenül emelkedett CRP szint jelen lehet minden TMA formában, PTX3 szint 
emelkedés azonban csak atípusos és típusos HUS-ban valamint szekunder TMA-ban 
volt kimutatható, trombotikus trombocitopéniás purpurában hiányzott. Mindkét 
pentraxin összefüggést mutatott a betegség súlyosságának laboratóriumi jeleivel. 
Emellett a PTX3 szint emelkedése korrelált a komplement konzumpció mértékével in 
vivo és csökkentette az alternatív út hemolítikus aktivitását in vitro, ami a lokálisan 
emelkedett PTX3 szint endoteliális károsodással szembeni véd  szerepére utal TMA 
akut szakaszában. A HF és anti-HF antitestek köt désének vizsgálata során 
azonosítottunk három lineáris antitest köt  epitópot a regulátor C terminális szakaszán 
és egyet a HF-ral homológ H faktor rokon-1 fehérjén. Az epitópok térbeli 
elhelyezkedése arra utal, hogy a lineáris struktúrák együttesen alkotják az antitest 
köt helyet a fehérje harmadlagos szerkezetén, és ezek átfedése a HF egyéb ligandjainak 
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